Home Cart Sign in  
Chemical Structure| 915087-33-1 Chemical Structure| 915087-33-1

Structure of Enzalutamide
CAS No.: 915087-33-1

Chemical Structure| 915087-33-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. It also activates autophagy.

Synonyms: MDV3100

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Hwang, Dong-Jin ; He, Yali ; Ponnusamy, Suriyan ; Thiyagarajan, Thirumagal ; Mohler, Michael L. ; Narayanan, Ramesh , et al.

Abstract: A major challenge for new drug discovery in the area of androgen receptor (AR) antagonists lies in predicting the druggable properties that will enable small mols. to retain their potency and stability during further studies in vitro and in vivo. Indole (compound 8) is a first-in-class AR antagonist with very high potency (IC50 = 0.085 μM) but is metabolically unstable. During the metabolic studies described herein, we synthesized new small mols. that exhibit significantly improved stability while retaining potent antagonistic activity for an AR. This structure-activity relationship (SAR) study of more than 50 compounds classified with three classes (Class I, II, and III) and discovered two compounds (32c and 35i) that are potent AR antagonists (e.g., IC50 = 0.021 μM, T1/2 = 120 min for compound 35i). The new antagonists exhibited improved in vivo pharmacokinetics (PK) with high efficacy antiandrogen activity in Hershberger and antiandrogen Enz-Res tumor xenograft models that overexpress AR (LNCaP-AR).

Purchased from AmBeed: ;

Alternative Products

Product Details of Enzalutamide

CAS No. :915087-33-1
Formula : C21H16F4N4O2S
M.W : 464.44
SMILES Code : CC1(C(N(C(N1C2=CC(F)=C(C(NC)=O)C=C2)=S)C3=CC(C(F)(F)F)=C(C#N)C=C3)=O)C
Synonyms :
MDV3100
MDL No. :MFCD14155804
InChI Key :WXCXUHSOUPDCQV-UHFFFAOYSA-N
Pubchem ID :15951529

Safety of Enzalutamide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Androgen Receptor

    Androgen Receptor, IC50:36 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Myc-CaP cells 50 µM >12 months To generate Enzalutamide-resistant cell lines, it was found that immune-related signaling pathways were suppressed in resistant cells PMC10163595
C4-2B cells 20 µM To study the mechanisms of Enzalutamide resistance, it was found that immune-related signaling pathways were suppressed in resistant cells PMC10163595
PC-3 10 μΜ 5 days Enzalutamide treatment did not induce senescence in PC-3 cells but increased CDC6 levels. PMC10386253
C4-2B 10 μΜ 5 days Enzalutamide treatment did not induce senescence in C4-2B cells but increased CDC6 levels. PMC10386253
LNCaP 10 μΜ 5 days Enzalutamide treatment induced senescence in LNCaP cells via reduction of the replication licensing factor CDC6. PMC10386253
CWR22Rv1 cells 20 μM 3 and 5 days To evaluate the combined inhibitory effect of Enzalutamide and Niclosamide on CWR22Rv1 cells, the results showed significant growth inhibition with the combination treatment. PMC4058390
C4-2B MR cells 20 μM 48 h To evaluate the inhibitory effect of Enzalutamide on C4-2B MR cells, the results showed limited growth inhibition of C4-2B MR cells by Enzalutamide. PMC4058390
VCaP cells 5 µM 48 h To investigate the effect of ROR-γ antagonists on AR-V7 gene expression, results showed that XY018 and SR2211 significantly inhibited AR-V7 gene expression. PMC5030109
C4-2B cells 5 µM 48 h To investigate the effect of ROR-γ antagonists on AR gene expression, results showed that SR2211 significantly inhibited AR gene expression. PMC5030109

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
FVB mice Myc-CaP tumor model Oral 25 mg/kg 5 days per week for 2 weeks To study the effects of Enzalutamide on immune cells in the tumor microenvironment, it was found that Enzalutamide treatment decreased CD8+ T-cell numbers and increased M-MDSC and PD-L1 expression PMC10163595
SCID mice LNCaP and C4-2B xenograft models Oral gavage 10 mg/kg 8 consecutive days Enzalutamide treatment induced senescence in LNCaP xenografts, reduced CDC6 levels, increased p21WAF1/Cip1 expression, and attenuated EMT. In C4-2B xenografts, Enzalutamide treatment did not induce senescence but increased CDC6 levels and EMT activity. PMC10386253
SCID mice CWR22Rv1 tumor model Oral 25 mg/kg 3 weeks To evaluate the combined inhibitory effect of Enzalutamide and Niclosamide on CWR22Rv1 tumors, the results showed significant tumor growth inhibition with the combination treatment. PMC4058390
Mice C4-2B xenograft model Intraperitoneal injection 5 mg/kg 5 times a week for 24 days To investigate the effect of SR2211 on tumor growth in the C4-2B xenograft model, results showed that SR2211 significantly inhibited tumor growth. PMC5030109
Mice Ptenpc-/- mice Oral 30 mg/kg Daily for 12 weeks Anti-IL23 treatment can reverse castration resistance in prostate cancer and enhance the efficacy of ENZA. PMC6461206

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01650194 Metastatic Castration-Resistan... More >>t Prostate Cancer Less << Phase 2 Completed - United States, Texas ... More >> Site US2492 MD Anderson Cancer Ctr Houston, Texas, United States, 77030 Less <<
NCT03478904 Prostate Cancer Phase 1 Recruiting April 30, 2019 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT03305224 Castration-resistant Prostate ... More >>Cancer Bone Metastases Less << Phase 2 Recruiting December 2019 Japan ... More >> Osaka City University Graduate School of Medicine Recruiting Osaka, Japan, 545-8585 Contact: Taro Iguchi, MD, PhD Less <<
NCT02286921 Castration Resistant Metastati... More >>c Prostate Cancer Less << Phase 2 Active, not recruiting December 2019 United States, District of Col... More >>umbia Sibley Memorial Hospital Washington, District of Columbia, United States, 20016 United States, Maryland SKCCC at Johns Hopkins Baltimore, Maryland, United States, 21205 Less <<
NCT02300610 Bladder Cancer ... More >> Carcinoma, Transitional Cell Renal Pelvis Cancer Ureter Cancer Urethra Cancer Less << Phase 1 Active, not recruiting August 2019 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Minnesota University of Minnesota, Masonic Cancer Center Minneapolis, Minnesota, United States, 55455 Less <<
NCT03531827 Metastatic Castration Resistan... More >>t Prostate Cancer Prostate Neoplasms Less << Phase 2 Recruiting June 30, 2020 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT01911715 Healthy Subjects|Pharmacokinet... More >>ics of MDV3100 Less << PHASE1 COMPLETED 2025-07-11 PRA International, Zuidlaren, ... More >>9471GP, Netherlands Less <<
NCT01565928 Prostate Cancer PHASE1 COMPLETED 2018-02-26 Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States Less <<
NCT03246347 Prostate Cancer ... More >> Prostate Adenocarcinoma Less << Phase 2 Recruiting August 2020 United States, North Carolina ... More >> Levine Cancer Institute Recruiting Charlotte, North Carolina, United States, 28204 Contact: Sandra Samu-Arce, RN    980-993-5484    sandra.samuarce@atriumhealth.org Less <<
NCT02254785 Metastatic Castration-Resistan... More >>t Prostatic Cancer Less << Phase 2 Active, not recruiting May 2020 Australia, Victoria ... More >> Box Hill Hospital Box Hill, Victoria, Australia, 3128 Monash Health-Monash Medical Centre Clayton, Victoria, Australia, 3168 Peter MacCallum Cancer Centre Melbourne, Victoria, Australia, 3000 Canada, Alberta Tom Baker Cancer Cantre Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia BCCA - Kelowna Kelowna, British Columbia, Canada, V1Y 5J3 BCCA- Vancouver Center Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Manitoba CancerCare Manitoba Winnipeg, Manitoba, Canada, R3E 0V9 Canada, Nova Scotia QEII Health Sciences Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Durham Regional Cancer Centre (Lakeridge Health) Oshawa, Ontario, Canada, L1G 2B9 The Ottawa Hospital Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Jewish General Hospital Montreal, Quebec, Canada, H3T 1E2 Canada, Saskatchewan Saskatoon Cancer Center Saskatoon, Saskatchewan, Canada, 27N 4H4 Less <<
NCT03314324 Metastatic Castrate-resistant ... More >>Prostate (CRPC) Cancer Less << Phase 2 Recruiting January 2022 France ... More >> Gustave Roussy Recruiting Villejuif, Val De Marne, France, 94805 Contact: Karim FIZAZI, MD    0142114317 ext +33    karim.fizazi@gustaveroussy.fr    Contact: Geraldine MARTINEAU, MD    0142115607 ext +33    geraldine.martineau@gustaveroussy.fr    Principal Investigator: Karim FIZAZI, MD Less <<
NCT03344211 Castration-Resistant Prostate ... More >>Carcinoma Prostate Carcinoma Metastatic in the Bone Stage IV Prostate Cancer Less << Phase 2 Recruiting November 21, 2023 United States, California ... More >> USC / Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Cheryl Kefauver, RN    323-865-0459    Cheryl.Kefauver@med.usc.edu    Principal Investigator: David I Quinn, MD          Cedars Sinai Medical Center Not yet recruiting Los Angeles, California, United States, 90048 Contact: Edwin M. Posadas    310-423-7600    Edwin.posadas@csmc.edu    Principal Investigator: Edwin M. Posadas Less <<
NCT02215096 Cancer Phase 1 Recruiting December 2, 2019 United States, California ... More >> GSK Investigational Site Completed Duarte, California, United States, 91010 GSK Investigational Site Completed Los Angeles, California, United States, 90089 GSK Investigational Site Recruiting Los Angeles, California, United States, 90095 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    United States, District of Columbia GSK Investigational Site Recruiting Washington, District of Columbia, United States, 20007 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    United States, Michigan GSK Investigational Site Recruiting Detroit, Michigan, United States, 48201 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    United States, New York GSK Investigational Site Completed New York, New York, United States, 10016 United States, Texas GSK Investigational Site Recruiting Houston, Texas, United States, 77030 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    United States, Utah GSK Investigational Site Terminated Salt Lake City, Utah, United States, 84112-5550 United Kingdom GSK Investigational Site Recruiting London, United Kingdom, SE1 9RT Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Sutton, United Kingdom, SM2 5PT Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com Less <<
NCT02588001 Prostate Cancer COMPLETED 2021-03-31 Kagawa University Faculty of M... More >>edicine, Kita-gun, Kagawa-prefecture, 761-0793, Japan|University of Miyazaki Faculty of Medicine, Miyazaki-city, Miyazaki-prefecture, 889-1692, Japan|Tokyo Medical Center, Meguro-ku, Tokyo, 152-8902, Japan|The Jikei university school of medicin, Minato-ku, Tokyo, 105-8461, Japan Less <<
NCT03395197 mCRPC Phase 3 Recruiting November 2024 United States, Alaska ... More >> Alaska Urological Institute dba Alaska Clinical Research Center Not yet recruiting Anchorage, Alaska, United States, 99503 United States, Arizona Urological Associates of Southern Arizona, PC Recruiting Tucson, Arizona, United States, 85715 Urological Associates of Southern Arizona, P.C. Recruiting Tucson, Arizona, United States, 85741 United States, California Marin Cancer Care, Inc. Not yet recruiting Greenbrae, California, United States, 94904 San Diego Clinical Trials Not yet recruiting San Diego, California, United States, 92120 United States, Colorado The Urology Center of Colorado Recruiting Denver, Colorado, United States, 80211 United States, Nebraska GU Research Network/Urology Cancer Center Recruiting Omaha, Nebraska, United States, 68130 United States, New Jersey New Jersey Urology, LLC Not yet recruiting Voorhees, New Jersey, United States, 08043 United States, New York Premier Medical Group of the Hudson Valley PC Not yet recruiting Poughkeepsie, New York, United States, 12601 Associated Medical Professionals of New York, PLLC Not yet recruiting Syracuse, New York, United States, 13210 United States, Ohio TriState urologic Services PSC Inc., dba The Urology Group Not yet recruiting Cincinnati, Ohio, United States, 45212 United States, South Carolina Carolina Urologic Research Center Recruiting Myrtle Beach, South Carolina, United States, 29572 United States, Tennessee Urology Associates P.C. Not yet recruiting Nashville, Tennessee, United States, 37209 United States, Utah University of Utah, Huntsman Cancer Hospital Recruiting Salt Lake City, Utah, United States, 84112 University of Utah, Huntsman Cancer Institute Recruiting Salt Lake City, Utah, United States, 84112 Less <<
NCT01911728 Pharmacokinetics of MDV3100 ... More >> Castration Resistant Prostate Cancer (CRPC) Less << Phase 1 Completed - South Africa ... More >> Parexel George, South Africa Parexel/Qdot Pharma Port Elizabeth, South Africa Less <<
NCT01901133 Pharmacokinetics of MDV3100|He... More >>althy Subjects|Kidney Diseases Less << PHASE1 COMPLETED 2025-01-12 Arensia, Chisinau, Moldova, Re... More >>public of Less <<
NCT01995513 Prostate Cancer Phase 4 Active, not recruiting May 31, 2024 -
NCT02012296 Hormone-resistant Prostate Can... More >>cer Recurrent Prostate Cancer Stage IV Prostate Cancer Less << Phase 1 Phase 2 Recruiting December 1, 2021 United States, Illinois ... More >> University of Chicago Comprehensive Cancer Center Recruiting Chicago, Illinois, United States, 60637-1470 Contact: Kelly O'Connor    773-702-4653    koconnor@medicine.bsd.uchicago.edu    Principal Investigator: Russell Z. Szmulewitz          Cancer Care Specialists of Central Illinois (Decatur) /Decatur Memorial Hospital Recruiting Decatur, Illinois, United States, 62526 Contact: James Wade, MD    217-876-6600       NorthShore University Health System Recruiting Evanston, Illinois, United States, 60201 Contact: Daniel Shevrin, MD    224-364-7100    dshevrin@northshore.org    United States, Michigan Wayne State University Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Elisabeth Heath, MD    313-576-8624    heathe@karmanos.org Less <<
NCT02799745 Prostate Cancer Phase 2 Active, not recruiting August 2020 -
NCT01995513 - Active, not recruiting - -
NCT02607228 Metastatic Castrate-Resistant ... More >>Prostate Cancer Less << Phase 1 Phase 2 Active, not recruiting December 2018 United States, California ... More >> San Francisco, California, United States, 94158 United States, Maryland Baltimore, Maryland, United States, 21231 United States, Massachusetts Boston, Massachusetts, United States, 02114 United States, North Carolina Durham, North Carolina, United States, 27710 Less <<
NCT02491411 Hormone-Resistant Prostate Can... More >>cer Metastatic Prostate Carcinoma Prostate Adenocarcinoma Stage IV Prostate Cancer Less << Not Applicable Terminated(The study is termin... More >>ated due to lower enrollment) Less << - United States, Maryland ... More >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 Less <<
NCT01885949 Prostate Cancer Phase 2 Active, not recruiting June 2019 United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT02125357 Metastatic Castration-Resistan... More >>t Prostate Cancer Less << Phase 2 Active, not recruiting July 2019 Canada, British Columbia ... More >> BC Cancer Agency - Abbotsford Abbotsford, British Columbia, Canada, V2S 0C2 BC Cancer Agency - Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BC Cancer Agency - Centre for the North Prince George, British Columbia, Canada, V2N 7E9 BC Cancer Agency - Fraser Valley Surrey, British Columbia, Canada, V3V 1Z2 Vancouver Prostate Centre Vancouver, British Columbia, Canada, V5Z 1M9 BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 BC Cancer Agency - Vancouver Island Victoria, British Columbia, Canada, V8R 6V5 Less <<
NCT02833883 Prostate Cancer ... More >> Castration Resistant Prostate Cancer Less << Phase 1 Recruiting July 2019 United States, California ... More >> University of California San Francisco Recruiting San Francisco, California, United States, 94143 Contact: Felix Feng, MD    415-502-7222       United States, Maryland John Hopkins Medical Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Emmanuel Antonarakis, MBBCh    410-464-6641       Principal Investigator: Emmanuel Antonarakis, MBBCh          United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Dana Rathkopf, MD    646-422-4379       Contact: Wassim Abida, MD, PhD    646-422-4633       Principal Investigator: Dana Rathkopf, MD          United States, Washington University of Washington School of Medicine Recruiting Seattle, Washington, United States, 98109 Contact: Heather Cheng, MD, PhD    206-606-7486       Principal Investigator: Heather Cheng, MD, PhD Less <<
NCT02749903 Salivary Cancer Phase 2 Active, not recruiting - -
NCT01091103 Metastatic Progressive Castrat... More >>ion-resistant Prostate Cancer Less << PHASE2 COMPLETED 2013-08-31 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77303, United States Less <<
NCT02669771 - Active, not recruiting November 2018 Japan ... More >> Aichi, Japan Akita, Japan Aomori, Japan Chiba, Japan Ehime, Japan Fukui, Japan Fukuoka, Japan Fukushima, Japan Gifu, Japan Gunma, Japan Hiroshima, Japan Hokkaido, Japan Hyogo, Japan Ibaraki, Japan Ishikawa, Japan Iwate, Japan Kagawa, Japan Kagoshima, Japan Kanagawa, Japan Kochi, Japan Kumamoto, Japan Kyoto, Japan Mie, Japan Miyagi, Japan Miyazaki, Japan Nagano, Japan Nagasaki, Japan Nara, Japan Niigata, Japan Oita, Japan Okayama, Japan Okinawa, Japan Osaka, Japan Saga, Japan Saitama, Japan Shiga, Japan Shimane, Japan Shizuoka, Japan Tochigi, Japan Tokushima, Japan Tokyo, Japan Tottori, Japan Toyama, Japan Wakayama, Japan Yamagata, Japan Yamaguchi, Japan Yamanashi, Japan Less <<
NCT02885649 Clear Cell Renal Cell Carcinom... More >>a Stage I Renal Cell Cancer Less << Early Phase 1 Recruiting January 2020 United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Eric A. Singer    732-235-8675    singerea@cinj.rutgers.edu    Principal Investigator: Eric A. Singer Less <<
NCT02491411 - Terminated(The study is termin... More >>ated due to lower enrollment) Less << - -
NCT01091103 Metastatic Progressive Castrat... More >>ion-resistant Prostate Cancer Less << PHASE2 COMPLETED 2013-08-31 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77303, United States Less <<
NCT02640534 Cancer of the Prostate ... More >> Prostate Cancer Less << Phase 2 Recruiting June 2026 Switzerland ... More >> Kantonsspital Aarau Recruiting Aarau, Switzerland, 5001 Contact: Tobias Wehrhahn, Dr. med.    +41 62 838 60 50    tobias.wehrhahn@ksa.ch    Principal Investigator: Tobias Wehrhahn, Dr. med.          Universitaetsspital Basel Recruiting Basel, Switzerland, 4031 Contact: Sacha Rothschild, MD    +41 61 265 25 25    sacha.rothschild@usb.ch    Principal Investigator: Sacha Rothschild, MD          Istituto Oncologico della Svizzera Italiana (IOSI) Recruiting Bellinzona, Switzerland, 6500 Contact: Ricardo Pereira Mestre, MD    +41 91 811 84 46    ricardo.pereiramestre@eoc.ch    Principal Investigator: Ricardo Pereira Mestre, MD          Kantonsspital Graubuenden Recruiting Chur, Switzerland, 7000 Contact: Richard Cathomas, MD    +41 81 256 66 95    richard.cathomas@ksgr.ch    Principal Investigator: Richard Cathomas, MD          Spital Thurgau AG Recruiting Frauenfeld, Switzerland, CH-8500 Contact: Regina Woelkly, MD    +41 52 723 76 91    regina.woelkly@stgag.ch    Principal Investigator: Regina Woelkly, MD          Hôpitaux Universitaires de Genève Recruiting Genève 14, Switzerland, 1211 Contact: Anna Patrikidou, MD    +41 79 553 60 99    anna.patrikidou@hcuge.ch    Principal Investigator: Anna Patrikidou, MD          CCAC Lausanne Recruiting Lausanne, Switzerland, 1004 Contact: Pierre Bohanes, MD    +41 (21) 646 79 94    pbohanes@bluewin.ch    Principal Investigator: Pierre Bohanes, MD          Luzerner Kantonsspital Recruiting Luzern 16, Switzerland, 6000 Contact: Beat Müller, MD    +41 41 205 58 60    beat.mueller@luks.ch    Principal Investigator: Beat Müller, MD          Hôpital du Valais Recruiting Martigny, Switzerland, 1920 Contact: Sandro Anchisi, MD    +41 27 603 90 00    sandro.anchisi@hopitalvs.ch    Principal Investigator: Sandro Anchisi, MD          Kantonsspital Olten Recruiting Olten, Switzerland, CH-4600 Contact: Walter Mingrone, MD    41-62-311-4241    wmingrone_ol@spital.ktso.ch    Principal Investigator: Walter Mingrone, MD          Hôpital du Valais Recruiting Sion, Switzerland, 1951 Contact: Sandro Anchisi, MD    +41 27 603 45 00    sandro.anchisi@hopitalvs.ch    Principal Investigator: Sandro Anchisi, MD          Bürgerspital Solothurn Recruiting Solothurn, Switzerland, CH-4500 Contact: Philippe von Burg, MD    +41 32 627 47 00    philippe.vonburg@spital.so.ch    Principal Investigator: Philippe von Burg, MD          Kantonsspital St. Gallen Recruiting St. Gallen, Switzerland, 9007 Contact: Christian Rothermundt, MD    +41 71 494 11 63    christian.rothermundt@kssg.ch    Principal Investigator: Christian Rothermundt, MD          Kantonsspital Winterthur Recruiting Winterthur, Switzerland, 8401 Contact: Natalie Fischer, MD    +41 052 266 40 87    natalie.fischer@ksw.ch    Principal Investigator: Natalie Fischer, MD          Stadtspital Triemli Recruiting Zürich, Switzerland, 8063 Contact: Aleksandra Marek, Dr. med.    +41 (44) 466 11 11    aleksandra.marek@triemli.zuerich.ch    Principal Investigator: Aleksandra Marek, Dr. med.          UniversitätsSpital Zürich Recruiting Zürich, Switzerland, 8091 Contact: Thomas Hermanns, MD    +41 44 255 11 11    thomas.hermanns@usz.ch    Principal Investigator: Thomas Hermanns, MD Less <<
NCT02935205 Metastatic Prostate Carcinoma ... More >> Recurrent Prostate Carcinoma Stage IV Prostate Cancer Less << Phase 1 Phase 2 Recruiting December 2020 United States, California ... More >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Chong-Xian Pan    916-734-3771    cxpan@ucdavis.edu    Principal Investigator: Chong-Xian Pan Less <<
NCT02555189 Hormone-Resistant Prostate Can... More >>cer Metastatic Prostate Carcinoma Prostate Carcinoma Metastatic in the Bone Stage IV Prostate Cancer Less << Phase 1 Phase 2 Recruiting May 2021 United States, Michigan ... More >> University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: David Smith, MD    734-763-6537       United States, New York Roswell Park Cancer Institute Recruiting Buffalo, New York, United States, 14263 Contact: Gurkamal Chatta, MD       Gurkamal.Chatta@RoswellPark.org    Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Susan Slovin, MD, PhD    646-422-4470       United States, Pennsylvania Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: William Kevin Kelly, MD    215-955-8874       Contact: Clinical Trials Office    215-955-1661       Principal Investigator: William Kevin Kelly, MD          Sub-Investigator: Robert Den, MD          Sub-Investigator: Jean Hoffman-Censits, MD          Sub-Investigator: Jianqing Lin, MD          Sub-Investigator: Leonard Gomella, MD          Sub-Investigator: Edouard Trabulsi, MD          Sub-Investigator: Costas Lallas, MD Less <<
NCT03704519 Cerebrovascular Circulation Phase 1 Recruiting July 24, 2019 United Kingdom ... More >> Academic Neuroscience Centre, Kings College Recruiting London, United Kingdom, SE5 8AF Less <<
NCT02091960 - Active, not recruiting - -
NCT02091960 HER2 Amplified ... More >> Advanced Breast Cancer Human Epidermal Growth Factor Receptor 2 (HER2) Less << Phase 2 Active, not recruiting December 2019 -
NCT01547299 Prostate Cancer Phase 2 Completed - United States, Massachusetts ... More >> Boston, Massachusetts, United States, 02215 United States, Washington Seattle, Washington, United States, 98195 Canada, British Columbia Vancouver, British Columbia, Canada, V5Z 1M9 Canada, Ontario Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT01547299 - Completed - -
NCT02339168 Prostate Cancer Phase 1 Active, not recruiting December 2019 United States, California ... More >> University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 Less <<
NCT02099864 Castration-Resistant Prostate ... More >>Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Soft Tissues|Metastatic Prostate Adenocarcinoma|Recurrent Prostate Carcinoma|Stage III Prostate Adenocarcinoma AJCC v7|Stage IV Prostate Adenocarcinoma AJCC v7 Less << PHASE2 COMPLETED 2024-07-08 UCSF Medical Center-Mount Zion... More >>, San Francisco, California, 94115, United States|OHSU Knight Cancer Institute, Portland, Oregon, 97239, United States Less <<
NCT01597193 Breast Cancer Phase 1 Completed - United States, Colorado ... More >> ATTN-Research Pharmacist Aurora, Colorado, United States, 80045 University of Colorado Cancer Center Aurora, Colorado, United States, 80045 University of Colorado Hospital, Anschutz Outpatient Pavilion Aurora, Colorado, United States, 80045 United States, Connecticut Connecticut Multispecialty Group Enfield, Connecticut, United States, 06082 United States, Florida Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Mississippi The West Clinic, PC Corinth, Mississippi, United States, 38834 The West Clinic Southaven, Mississippi, United States, 38671 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10022 Memorial Sloan Kettering Cancer Center - IDS Pharmacy New York, New York, United States, 10065 Memorial Sloan Kettering Cancer Center - OPD Pharmacy New York, New York, United States, 10065 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Tennessee The West Clinic Germantown, Tennessee, United States, 38138 The West Clinic Memphis, Tennessee, United States, 38104 The West Clinic Memphis, Tennessee, United States, 38120 Tennessee Oncology, PLLC. Nashville, Tennessee, United States, 37203 The Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 Less <<
NCT02007512 - Active, not recruiting - -
NCT01663415 Metastatic Castration-Resistan... More >>t Prostate Cancer Less << PHASE2 WITHDRAWN 2025-10-14 -
NCT02057939 Prostate Cancer Phase 2 Active, not recruiting March 2019 United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 Wake Forest Baptist Health Winston-Salem, North Carolina, United States, 27157 Less <<
NCT02489123 Ann Arbor Stage I Mantle Cell ... More >>Lymphoma Ann Arbor Stage II Mantle Cell Lymphoma Ann Arbor Stage III Mantle Cell Lymphoma Ann Arbor Stage IV Mantle Cell Lymphoma Recurrent Mantle Cell Lymphoma Refractory Mantle Cell Lymphoma Less << Not Applicable Recruiting - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Ajay K. Gopal    206-606-2037    agopal@uw.edu    Principal Investigator: Ajay K. Gopal Less <<
NCT02452008 Prostate Cancer Phase 2 Recruiting July 2021 United States, District of Col... More >>umbia Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Janice Powers, RN    202-660-5772    jpower22@JHMI.EDU    Principal Investigator: Channing Paller, MD          United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Maha Hussain, MD    312-908-5487    maha.hussain@northwestern.edu    Principal Investigator: Maha Hussain, MD          University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Russel Szmulewitz, MD    773-702-7609    rszmulew@medicine.bsd.uchicago.edu    Contact: Kelly O'Connor    773-702-4653    koconnor@medicine.bsd.uchicago.edu    Principal Investigator: Russel Szmulewitz, MD          United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21205 Contact: Channing Paller, MD    410-614-6321    cpaller@JHMI.EDU    Contact: Irina Rifkind, RN    410-502-2043    irifkin1@JHMI.EDU    Principal Investigator: Channing Paller, MD Less <<
NCT03709550 Castration Levels of Testoster... More >>one Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma in the Soft Tissue Prostate Carcinoma Metastatic in the Bone PSA Level Greater Than or Equal to Two PSA Progression Stage IV Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8 Less << Phase 1 Phase 2 Not yet recruiting August 31, 2020 United States, New York ... More >> Roswell Park Cancer Institute Not yet recruiting Buffalo, New York, United States, 14263 Contact: Gurkamal S. Chatta    716-845-3117    Gurkamal.Chatta@roswellpark.org    Principal Investigator: Gurkamal S. Chatta Less <<
NCT02689427 Breast Cancer Phase 2 Recruiting September 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT01302041 Prostate Cancer PHASE2 COMPLETED 2017-04-27 Site BE1003, Brussels, 1090, B... More >>elgium|Site BE1001, Brussels, 1200, Belgium|Site BE1002, Kortrijk, 8500, Belgium|Site BE1005, Leuven, 3000, Belgium|Site CZ3006, Olomouc, 77520, Czechia|Site CZ3002, Praha 6, 16000, Czechia|Site DK4001, Aarhus N, 8200, Denmark|Site DK4004, Copenhagen, DK-2100, Denmark|Site DK4002, Herlev, 2730, Denmark|Site DE5005, Aachen, 51074, Germany|Site DE5007, Bonn, 53111, Germany|Site DE5003, Hannover, 30625, Germany Less <<
NCT01889238 Advanced, Androgen Receptor Po... More >>sitive Triple Negative Breast Cancer Less << PHASE2 COMPLETED 2024-01-10 Rocky Mountain Cancer Centers,... More >> Colorado Springs, Colorado, 80907, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, 80228, United States|Rocky Mountain Cancer Center Sky Ridge, Lone Tree, Colorado, 80124, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, 80124, United States|Florida Cancer Specialists, Altamonte Springs, Florida, 32701, United States|Florida Cancer Specialists, Bonita Springs, Florida, 34135, United States|Florida Cancer Specialists, Bradenton, Florida, 34209, United States|Florida Cancer Specialists, Brandon, Florida, 33511, United States|Florida Cancer Specialists, Cape Coral, Florida, 33914, United States|Florida Cancer Specialists, Clearwater, Florida, 33761, United States|Florida Cancer Specialists, Fort Myers, Florida, 33905, United States|Florida Cancer Specialist South Division, Fort Myers, Florida, 33908, United States|Florida Cancer Specialists, Fort Myers, Florida, 33908, United States|Florida Cancer Specialists, Fort Myers, Florida, 33916, United States|Florida Cancer Specialists, Gainesville, Florida, 32605, United States|Florida Cancer Specialists, Hudson, Florida, 34667, United States|Florida Cancer Specialists, Largo, Florida, 33770, United States|Florida Cancer Specialists, Naples, Florida, 34102, United States|Florida Cancer Specialists, New Port Richey, Florida, 34655, United States|Florida Cancer Specialists, Orange City, Florida, 32763, United States|Florida Cancer Specialists, Orlando, Florida, 32806, United States|Florida Cancer Specialists, Port Charlotte, Florida, 33980, United States|Florida Cancer Specialists, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Florida Cancer Specialists, Sarasota, Florida, 34236, United States|Florida Cancer Specialists, Spring Hill, Florida, 34608, United States|Florida Cancer Specialists, Tampa, Florida, 33607, United States|Florida Cancer Specialists, Tavares, Florida, 32778, United States|Florida Cancer Specialists, Venice, Florida, 34285, United States|Florida Cancer Specialists, Venice, Florida, 34292, United States|Northwestern Medical Faculty Foundation(NMFF)/ Women's Cancer Center Shared Laboratories, Chicago, Illinois, 60611, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, 60611, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|The University of Chicago Medical Center, Investigational Drug Service Department of Pharmacy, Chicago, Illinois, 60637, United States|The University of Chicago, Chicago, Illinois, 60637, United States|University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, 60451, United States|Indiana University Health Hospital, Indianapolis, Indiana, 46202, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Investigational Drug Services, Indianapolis, Indiana, 46202, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, 46202, United States|Springmill Medical Clinic, Indianapolis, Indiana, 46290, United States|Oncology Hematology Care, Inc., Crestview Hills, Kentucky, 41017, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|The West Clinic, PC, Corinth, Mississippi, 38834, United States|The West Clinic, PC, Southaven, Mississippi, 38671, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, 63110, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, 63129, United States|Siteman Cancer Center-West County, Saint Louis, Missouri, 63141, United States|Siteman Cancer Center, Saint Peters, Missouri, 63376, United States|Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, 07962, United States|Memorial Sloan Kettering - I Chemotherapy Practice/Investigational Drug Service, New York, New York, 10065, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Cone Health Cancer Center, Greensboro, North Carolina, 27403, United States|Wesley Long Community Hospital, Greensboro, North Carolina, 27403, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45211, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45219, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45230, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45236, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45242, United States|Oncology Hematology Care, Inc., Fairfield, Ohio, 45014, United States|Greenville Health System, Greenville, South Carolina, 29605, United States|Greenville Health System, Seneca, South Carolina, 29672, United States|Greenville Health System, Spartanburg, South Carolina, 29307, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, 37055, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, 37067, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, 37066, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, 37076, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, 37087, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, 37090, United States|The West Clinic, PC, Memphis, Tennessee, 38104, United States|The West Clinic, PC, Memphis, Tennessee, 38120, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, 37129, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, 37204, United States|Vanderbilt Health Pharmacy One Hundred Oaks, Nashville, Tennessee, 37204, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37205, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37207, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37211, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, 37232, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, 37167, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Texas Oncology - Memorial City, Houston, Texas, 77024, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, 75601, United States|Texas Oncology-Tyler, Tyler, Texas, 75702, United States|Virginia Cancer Institute, Mechanicsville, Virginia, 23116-1844, United States|Virginia Cancer Institute, Midlothian, Virginia, 23114, United States|Virginia Oncology Associates, Newport News, Virginia, 23606, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Virginia Cancer Institute, Richmond, Virginia, 23230, United States|Virginia Cancer Institute, Richmond, Virginia, 23235-4730, United States|Virginia Oncology Associates, Virginia Beach, Virginia, 23456, United States|UZA, Edegem, Antwerpen, 2650, Belgium|Institut Jules Bordet, Brussels, 1000, Belgium|British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|McGill University Health Centre-Cedars Cancer Centre, Montreal, Quebec, H4A 3J1, Canada|Department of Radiology, Dooradoyle, Limerick, Ireland|Pharmacy Department, Dublin 4, Ireland|3rd Floor,Oncology Link office, Dublin, 4, Ireland|Department of Radiology, Dublin, 4, Ireland|Institute for Cancer Research, Dublin, 7, Ireland|Mater Private Hospital, Dublin, 7, Ireland|Pharmacy Department, Dublin, 7, Ireland|Radiology Department, Dublin, 7, Ireland|Cancer Clinical Trials Unit, Mid-Western Cancer center, Limerick, Ireland|Pharmacy Department, Limerick, Ireland|Dipartimento di Oncologia Medica, IRCCS Ospedale San Raffaele, Milano, 20132, Italy|Farmacia (magazzino ricevimento merc), IRCCS Ospedale San Raffaele, Milano, 20132, Italy|U.O Farmaceutica, Nuovo Ospedale di Prato Palazzina dei servizi, Prato, 59100, Italy|U.O. Oncologia Medica, Nuovo Ospedale di Prato, Prato, 59100, Italy|Hospital Universitario HM Monteprincipe, Boadilla del Monte, Madrid, 28660, Spain|Grupo Hospitalario Quiron - Hospital Quiron Barcelona, Barcelona, 08023, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario Ramon Y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 Octubre, Madrid, 28041, Spain|Centro Intergral Oncologico Clara Campal, Madrid, 28050, Spain|Hospital de Madrid Norte-Sanchinarro., Madrid, 28050, Spain|Clinical Investigation and Research Unit, Brighton, England, BN2 5BE, United Kingdom|Pharmacy Department, Brighton, England, BN2 5BE, United Kingdom|Radiation Safety Service, Medical Physics Department, Brighton, England, BN2 5BE, United Kingdom|Histopathology Department, Nottingham, England, NG5 1PB, United Kingdom|Nottingham University Hospital, Nottingham, England, NG5 1PB, United Kingdom|Pharmacy Department, Nottingham, England, NG5 1PB, United Kingdom|Radiology Department, Nottingham, England, NG5 1PB, United Kingdom|Radiology Department, Nottingham, England, NG7 2UH, United Kingdom|Royal Cornwall Hospitals NHS trust, Truro, Cornwall, England, TR1 3LJ, United Kingdom|Department of Radiology, Truro, England, TR1 3LJ, United Kingdom|Pharmacy Department, Truro, England, TR1 3LJ, United Kingdom Less <<
NCT02642913 Hepatocellular Carcinoma Phase 1 Phase 2 Recruiting December 2019 United States, California ... More >> University of California San Francisco Recruiting San Francisco, California, United States, 94143 Contact: Robin K Kelley, MD    415-353-9888       United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Benjamin Tan, MD    314-747-7222       Principal Investigator: Benjamin Tan, MD          United States, New York Roswell Park Cancer Institute Recruiting Buffalo, New York, United States, 14263-0001 Contact: Iyer Renuka, MD    716-845-2300       Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: James Harding, MD    646-888-4314       Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: James Harding, MD    646-888-4314       Contact: Ghassan Abou-Alfa, MD    646-888-4184 Less <<
NCT01889238 Advanced, Androgen Receptor Po... More >>sitive Triple Negative Breast Cancer Less << PHASE2 COMPLETED 2024-01-10 Rocky Mountain Cancer Centers,... More >> Colorado Springs, Colorado, 80907, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, 80228, United States|Rocky Mountain Cancer Center Sky Ridge, Lone Tree, Colorado, 80124, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, 80124, United States|Florida Cancer Specialists, Altamonte Springs, Florida, 32701, United States|Florida Cancer Specialists, Bonita Springs, Florida, 34135, United States|Florida Cancer Specialists, Bradenton, Florida, 34209, United States|Florida Cancer Specialists, Brandon, Florida, 33511, United States|Florida Cancer Specialists, Cape Coral, Florida, 33914, United States|Florida Cancer Specialists, Clearwater, Florida, 33761, United States|Florida Cancer Specialists, Fort Myers, Florida, 33905, United States|Florida Cancer Specialist South Division, Fort Myers, Florida, 33908, United States|Florida Cancer Specialists, Fort Myers, Florida, 33908, United States|Florida Cancer Specialists, Fort Myers, Florida, 33916, United States|Florida Cancer Specialists, Gainesville, Florida, 32605, United States|Florida Cancer Specialists, Hudson, Florida, 34667, United States|Florida Cancer Specialists, Largo, Florida, 33770, United States|Florida Cancer Specialists, Naples, Florida, 34102, United States|Florida Cancer Specialists, New Port Richey, Florida, 34655, United States|Florida Cancer Specialists, Orange City, Florida, 32763, United States|Florida Cancer Specialists, Orlando, Florida, 32806, United States|Florida Cancer Specialists, Port Charlotte, Florida, 33980, United States|Florida Cancer Specialists, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Florida Cancer Specialists, Sarasota, Florida, 34236, United States|Florida Cancer Specialists, Spring Hill, Florida, 34608, United States|Florida Cancer Specialists, Tampa, Florida, 33607, United States|Florida Cancer Specialists, Tavares, Florida, 32778, United States|Florida Cancer Specialists, Venice, Florida, 34285, United States|Florida Cancer Specialists, Venice, Florida, 34292, United States|Northwestern Medical Faculty Foundation(NMFF)/ Women's Cancer Center Shared Laboratories, Chicago, Illinois, 60611, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, 60611, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|The University of Chicago Medical Center, Investigational Drug Service Department of Pharmacy, Chicago, Illinois, 60637, United States|The University of Chicago, Chicago, Illinois, 60637, United States|University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, 60451, United States|Indiana University Health Hospital, Indianapolis, Indiana, 46202, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Investigational Drug Services, Indianapolis, Indiana, 46202, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, 46202, United States|Springmill Medical Clinic, Indianapolis, Indiana, 46290, United States|Oncology Hematology Care, Inc., Crestview Hills, Kentucky, 41017, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|The West Clinic, PC, Corinth, Mississippi, 38834, United States|The West Clinic, PC, Southaven, Mississippi, 38671, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, 63110, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, 63129, United States|Siteman Cancer Center-West County, Saint Louis, Missouri, 63141, United States|Siteman Cancer Center, Saint Peters, Missouri, 63376, United States|Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, 07962, United States|Memorial Sloan Kettering - I Chemotherapy Practice/Investigational Drug Service, New York, New York, 10065, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Cone Health Cancer Center, Greensboro, North Carolina, 27403, United States|Wesley Long Community Hospital, Greensboro, North Carolina, 27403, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45211, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45219, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45230, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45236, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45242, United States|Oncology Hematology Care, Inc., Fairfield, Ohio, 45014, United States|Greenville Health System, Greenville, South Carolina, 29605, United States|Greenville Health System, Seneca, South Carolina, 29672, United States|Greenville Health System, Spartanburg, South Carolina, 29307, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, 37055, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, 37067, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, 37066, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, 37076, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, 37087, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, 37090, United States|The West Clinic, PC, Memphis, Tennessee, 38104, United States|The West Clinic, PC, Memphis, Tennessee, 38120, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, 37129, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, 37204, United States|Vanderbilt Health Pharmacy One Hundred Oaks, Nashville, Tennessee, 37204, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37205, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37207, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37211, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, 37232, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, 37167, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Texas Oncology - Memorial City, Houston, Texas, 77024, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, 75601, United States|Texas Oncology-Tyler, Tyler, Texas, 75702, United States|Virginia Cancer Institute, Mechanicsville, Virginia, 23116-1844, United States|Virginia Cancer Institute, Midlothian, Virginia, 23114, United States|Virginia Oncology Associates, Newport News, Virginia, 23606, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Virginia Cancer Institute, Richmond, Virginia, 23230, United States|Virginia Cancer Institute, Richmond, Virginia, 23235-4730, United States|Virginia Oncology Associates, Virginia Beach, Virginia, 23456, United States|UZA, Edegem, Antwerpen, 2650, Belgium|Institut Jules Bordet, Brussels, 1000, Belgium|British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|McGill University Health Centre-Cedars Cancer Centre, Montreal, Quebec, H4A 3J1, Canada|Department of Radiology, Dooradoyle, Limerick, Ireland|Pharmacy Department, Dublin 4, Ireland|3rd Floor,Oncology Link office, Dublin, 4, Ireland|Department of Radiology, Dublin, 4, Ireland|Institute for Cancer Research, Dublin, 7, Ireland|Mater Private Hospital, Dublin, 7, Ireland|Pharmacy Department, Dublin, 7, Ireland|Radiology Department, Dublin, 7, Ireland|Cancer Clinical Trials Unit, Mid-Western Cancer center, Limerick, Ireland|Pharmacy Department, Limerick, Ireland|Dipartimento di Oncologia Medica, IRCCS Ospedale San Raffaele, Milano, 20132, Italy|Farmacia (magazzino ricevimento merc), IRCCS Ospedale San Raffaele, Milano, 20132, Italy|U.O Farmaceutica, Nuovo Ospedale di Prato Palazzina dei servizi, Prato, 59100, Italy|U.O. Oncologia Medica, Nuovo Ospedale di Prato, Prato, 59100, Italy|Hospital Universitario HM Monteprincipe, Boadilla del Monte, Madrid, 28660, Spain|Grupo Hospitalario Quiron - Hospital Quiron Barcelona, Barcelona, 08023, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario Ramon Y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 Octubre, Madrid, 28041, Spain|Centro Intergral Oncologico Clara Campal, Madrid, 28050, Spain|Hospital de Madrid Norte-Sanchinarro., Madrid, 28050, Spain|Clinical Investigation and Research Unit, Brighton, England, BN2 5BE, United Kingdom|Pharmacy Department, Brighton, England, BN2 5BE, United Kingdom|Radiation Safety Service, Medical Physics Department, Brighton, England, BN2 5BE, United Kingdom|Histopathology Department, Nottingham, England, NG5 1PB, United Kingdom|Nottingham University Hospital, Nottingham, England, NG5 1PB, United Kingdom|Pharmacy Department, Nottingham, England, NG5 1PB, United Kingdom|Radiology Department, Nottingham, England, NG5 1PB, United Kingdom|Radiology Department, Nottingham, England, NG7 2UH, United Kingdom|Royal Cornwall Hospitals NHS trust, Truro, Cornwall, England, TR1 3LJ, United Kingdom|Department of Radiology, Truro, England, TR1 3LJ, United Kingdom|Pharmacy Department, Truro, England, TR1 3LJ, United Kingdom Less <<
NCT01664923 Prostate Cancer Phase 2 Completed - -
NCT02007512 Breast Cancer Phase 2 Active, not recruiting March 29, 2019 -
NCT01664923 - Completed - -
NCT02294461 Progressive Metastatic Prostat... More >>e Cancer Less << Phase 3 Active, not recruiting March 2020 -
NCT03751436 Castration Levels of Testoster... More >>one Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Metastatic Prostate Carcinoma in the Soft Tissue Prostate Carcinoma Metastatic in the Bone PSA Progression Stage IV Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8 Less << Phase 1 Phase 2 Not yet recruiting September 2022 United States, New York ... More >> Roswell Park Cancer Institute Not yet recruiting Buffalo, New York, United States, 14263 Contact: Gurkamal S. Chatta    716-845-3117    Gurkamal.Chatta@roswellpark.org    Principal Investigator: Gurkamal S. Chatta Less <<
NCT02064582 Prostate Cancer Phase 2 Active, not recruiting April 2019 United States, Texas ... More >> UT Southwestern Medical Center Dallas, Texas, United States, 75390 Less <<
NCT02294461 - Active, not recruiting - -
NCT02955394 Breast Cancer Phase 2 Recruiting November 2018 United States, Colorado ... More >> University of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Tiffany Colvin    720-848-0664    tiffany.colvin@ucdenver.edu    Principal Investigator: Anthony D Elias, MD          United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Monica Fornier, MD       fornierm@mskcc.org    Principal Investigator: Monica Fornier, MD          United States, Tennessee West Cancer Center Recruiting Germantown, Tennessee, United States, 38138 Contact: Gregory Vidal, MD       gvidal@westclinic.com    Principal Investigator: Gregory Vidal, MD Less <<
NCT02750358 Breast Cancer ... More >> Early Stage Triple Negative Breast Cancer Less << Phase 2 Active, not recruiting May 2019 United States, Connecticut ... More >> Hartford Healthcare Cancer Institute @ Hartford Hospital Hartford, Connecticut, United States, 06102 United States, New Jersey Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States, 07920 Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 United States, New York Kings County Hopsital Center Brooklyn, New York, United States, 11203 Coney Island Hospital Brooklyn, New York, United States, 11235 Woodhull Hospital Brooklyn, New York, United States Memorial Sloan Kettering Cancer Center at Commack Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Queens Hospital Center Jamaica, New York, United States, 11432 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan-Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York, United States, 11570 United States, Pennsylvania Lehigh Valley Health Network Allentown, Pennsylvania, United States, 18103 Less <<
NCT01302041 Prostate Cancer PHASE2 COMPLETED 2017-04-27 Site BE1003, Brussels, 1090, B... More >>elgium|Site BE1001, Brussels, 1200, Belgium|Site BE1002, Kortrijk, 8500, Belgium|Site BE1005, Leuven, 3000, Belgium|Site CZ3006, Olomouc, 77520, Czechia|Site CZ3002, Praha 6, 16000, Czechia|Site DK4001, Aarhus N, 8200, Denmark|Site DK4004, Copenhagen, DK-2100, Denmark|Site DK4002, Herlev, 2730, Denmark|Site DE5005, Aachen, 51074, Germany|Site DE5007, Bonn, 53111, Germany|Site DE5003, Hannover, 30625, Germany Less <<
NCT01974765 Advanced Epithelial Ovarian|Re... More >>current Epithelial Ovarian|Fallopian Tube|Primary Peritoneal Carcinoma Less << PHASE2 COMPLETED 2022-02-28 Memorial Sloan Kettering Cance... More >>r Center at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, 11570, United States Less <<
NCT02918968 Prostate Cancer Phase 4 Active, not recruiting March 2020 Japan ... More >> Site JP00024 Aichi, Japan Site JP00025 Aichi, Japan Site JP00010 Chiba, Japan Site JP00053 Chiba, Japan Site JP00038 Ehime, Japan Site JP00039 Fukuoka, Japan Site JP00040 Fukuoka, Japan Site JP00050 Fukuoka, Japan Site JP00051 Fukuoka, Japan Site JP00005 Gunma, Japan Site JP00043 Gunma, Japan Site JP00045 Gunma, Japan Site JP00035 Hiroshima, Japan Site JP00001 Hokkaido, Japan Site JP00002 Hokkaido, Japan Site JP00048 Hokkaido, Japan Site JP00054 Hokkaido, Japan Site JP00055 Ibaraki, Japan Site JP00019 Kanagawa, Japan Site JP00020 Kanagawa, Japan Site JP00021 Kanagawa, Japan Site JP00044 Kanagawa, Japan Site JP00026 Kyoto, Japan Site JP00006 Nagano, Japan Site JP00008 Nagano, Japan Site JP00041 Nagasaki, Japan Site JP00046 Nara, Japan Site JP00033 Okayama, Japan Site JP00027 Osaka, Japan Site JP00028 Osaka, Japan Site JP00029 Osaka, Japan Site JP00030 Osaka, Japan Site JP00031 Osaka, Japan Site JP00032 Osaka, Japan Site JP00042 Saga, Japan Site JP00009 Saitama, Japan Site JP00022 Shizuoka, Japan Site JP00049 Tochigi, Japan Site JP00037 Tokushima, Japan Site JP00011 Tokyo, Japan Site JP00013 Tokyo, Japan Site JP00014 Tokyo, Japan Site JP00016 Tokyo, Japan Site JP00017 Tokyo, Japan Site JP00018 Tokyo, Japan Site JP00052 Toyama, Japan Site JP00034 Yamaguchi, Japan Less <<
NCT01977651 Metastatic Castration-resistan... More >>t Prostate Cancer (mCRPC) Less << PHASE4 COMPLETED 2019-01-11 Site US10005, Anchorage, Alask... More >>a, 99503, United States|Site US10024, Detroit, Michigan, 48202, United States|Site US10026, Bronx, New York, 10461, United States|Site US10001, New York, New York, 10065, United States|Site US10014, New York, New York, 10065, United States|Site US10039, Syracuse, New York, 13210, United States|Site US10016, Durham, North Carolina, 27710, United States|Site US10008, Dallas, Texas, 75231, United States|Site US10025, Seattle, Washington, 98109, United States|Site AR54001, Berazategui, Buenos Aires, B1880BBF, Argentina|Site AR54006, Ciudad Autonoma de BuenosAires, Buenos Aires, C1426ANZ, Argentina|Site AR54002, Buenos Aires, Caba, C1120AAT, Argentina|Site AR54003, Cordoba, 5000, Argentina|Site AR54004, Santa Fe, S3000FFU, Argentina|Site AR54005, Tucuman, 4000, Argentina|Site AU61012, Kogarah, New South Wales, 2217, Australia|Site AU61005, Randwick, New South Wales, 2031, Australia|Site AU61011, Sydney, New South Wales, 2109, Australia|Site AU61001, Tweed Heads, New South Wales, 2485, Australia|Site AU61002, Nambour, Queensland, 4560, Australia|Site AU61007, Adelaide, South Australia, 5042, Australia|Site AU61004, Ballarat, Victoria, 3350, Australia|Site BE32004, Anderlecht, 1070, Belgium|Site BE32001, Kortrijk, 8500, Belgium|Site BE32003, Liege, B-4000, Belgium|Site CA15005, Abbotsford, British Columbia, V2S 3N5, Canada|Site CA15014, Halifax, Nova Scotia, B3H 2Y9, Canada|Site CA15004, Brampton, Ontario, L6T 4S5, Canada|Site CA15010, Scarborough, Ontario, M1S 4V5, Canada|Site CA15001, Quebec City, Quebec, G1R3S1, Canada|Site CL56001, Temuco, IX Region, 4810469, Chile|Site CL56004, Santiago, 8420383, Chile|Site CL56002, Temuco, 4781156, Chile|Site CL56003, Vina del Mar, 2540364, Chile|Site CZ42004, Praha 2, 12000, Czechia|Site CZ42002, Praha 6, 16000, Czechia|Site FI35803, Helsinki, 00290, Finland|Site FI35801, Oulu, 90220, Finland|Site FI35802, Tampere, 33520, Finland|Site FR33002, Lyon Cedex 03, 69437, France|Site FR33004, Rouen Cedex, 76031, France|Site FR33005, Suresnes, 92151, France|Site DE49009, Nürtingen, Baden-Württemberg, 72622, Germany|Site DE49003, Berlin, 12200, Germany|Site DE49001, Munster, 48149, Germany|Site HU36002, Sopron, Gyor-Moson Sopron, 9400, Hungary|Site IL97202, Kfar Saba, HaMerkaz, 44281, Israel|Site IL97201, Be'er Ya'akov, 70300, Israel|Site IL97203, Beer-Sheva, 84101, Israel|Site IL97205, Haifa, 31096, Israel|Site IL97204, Jerusalem, 91120, Israel|Site IL97208, Nahariya, 21000, Israel|Site IL97206, Petah-Tiqva, 49100, Israel|Site IL97207, Ramat Gan, 52621, Israel|Site IT39005, Meldola, Emilia-Romagna, 47014, Italy|Site IT39001, Cremona, Lombardia, 26100, Italy|Site IT39002, Arezzo, 52100, Italy|Site IT39003, Roma, 00144, Italy|Site KR82006, Seongnam-Si, Gyeonggi-do, 013620, Korea, Republic of|Site KR82007, Seoul, 03080, Korea, Republic of|Site KR82003, Seoul, 135-710, Korea, Republic of|Site KR82001, Seoul, 135-720, Korea, Republic of|Site KR82004, Seoul, 137-701, Korea, Republic of|Site NZ64001, Hamilton, 3204, New Zealand|Site SG65002, Singapore, 119228, Singapore|Site ES34007, Hospitalet de Llobregat, Barcelona, 08908, Spain|Site ES34005, Sabadell, Barcelona, 08208, Spain|Site ES34001, Pamplona, Navarra, 31008, Spain|Site ES34003, Barcelona, 08025, Spain|Site ES34004, Barcelona, 08035, Spain|Site ES34006, Madrid, 28050, Spain|Site SE46001, Goteborg, 41345, Sweden|Site SE46002, Orebro, 701 85, Sweden|Site TW88601, Kaohsiung, 81362, Taiwan|Site TW88603, Taipei City, 10048, Taiwan|Site GB44002, Sutton, Surrey, SM2 5PT, United Kingdom Less <<
NCT02203695 Adenocarcinoma of the Prostate Phase 2 Recruiting August 2025 United States, District of Col... More >>umbia Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Ashley Bruns    202-537-4000    abruns3@jhmi.edu    United States, Illinois University of Chicago Medical Center Recruiting Chicago, Illinois, United States, 60637 Contact: Fauzia Arif       farif@radonc.uchicago.edu    United States, Indiana Indiana University Not yet recruiting Lafayette, Indiana, United States, 47904 Contact: Stephanie Middleton    765-838-6871    smiddle3@iuhealth.org    United States, Maryland The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21287 Sub-Investigator: Charles Drake, M.D.          Sub-Investigator: Hans Hammers, M.D.          Sub-Investigator: Emmanuel Antonarakis, M.D.          Sub-Investigator: Samuel Denmeade, M.D.          Sub-Investigator: Channing Pallar, M.D.          Sub-Investigator: Hao Wang, Ph.D.          Sub-Investigator: Danny Song, M.D.          Sub-Investigator: Mario Eisenberger, M.D.          Sub-Investigator: Michael Carducci, M.D.          Sub-Investigator: Theodore DeWeese, M.D.          Suburban Hospital Recruiting Bethesda, Maryland, United States, 20814 Contact: Barbara Squiller    301-896-2719    bsquill1@jhmi.edu    United States, Michigan University of Michigan Health System Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Carolina Fernandez-Castillo       cefernan@med.umich.edu    Contact: Charles Leister       cleister@med.umich.edu    Karmanos Cancer Center Recruiting Detroit, Michigan, United States, 48201 Contact: Ted Chaperon       chaperon@karmanos.org    Principal Investigator: Peter Paximadis          Sub-Investigator: Elisabeth Heath          United States, Oregon Oregon Health Sciences University Recruiting Portland, Oregon, United States, 97239 Contact: Ryan Stewart       stewarry@ohsu.edu    Principal Investigator: Arthur Hung          United States, Utah University of Utah - Huntsman Cancer Center Not yet recruiting Salt Lake City, Utah, United States, 84112 Less <<
NCT02003924 Nonmetastatic Castration-Resis... More >>tant Prostate Cancer Prostate Cancer Cancer of the Prostate Less << Phase 3 Active, not recruiting May 31, 2020 -
NCT02677896 Metastatic Hormone Sensitive P... More >>rostate Cancer Less << Phase 3 Active, not recruiting December 2023 -
NCT02605863 Bladder Cancer PHASE2 TERMINATED 2025-02-18 University of Rochester, Roche... More >>ster, New York, 14642, United States Less <<
NCT02429193 Castration-resistant Prostate ... More >>Cancer Less << Phase 2 Active, not recruiting June 2018 Canada, British Columbia ... More >> British Columbia Cancer Agency, Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT03700099 Prostate Cancer ... More >> Castration-resistant Prostate Cancer Less << Phase 2 Not yet recruiting December 2021 Brazil ... More >> Instituto do Câncer do Estado de São Paulo Not yet recruiting São Paulo, SP, Brazil Contact: Ingrid Barbosa    +55 11 3893-3535    ingrid.barbosa@hc.fm.usp.br    Principal Investigator: Diogo Assed Bastos, MD Less <<
NCT02605863 Bladder Cancer PHASE2 TERMINATED 2025-02-18 University of Rochester, Roche... More >>ster, New York, 14642, United States Less <<
NCT02711956 Metastatic Castration-Resistan... More >>t Prostate Cancer Less << Phase 1 Phase 2 Recruiting June 2019 United States, California ... More >> University of California Los Angeles Medical Center Recruiting Los Angeles, California, United States University of California San Francisco Medical Center Recruiting San Francisco, California, United States United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States Karmanos Cancer Institute Recruiting Farmington Hills, Michigan, United States United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States Weill Cornell Medicine - New York Presbyterian Recruiting New York, New York, United States United States, Oregon Oregon Health & Science University Recruiting Portland, Oregon, United States United States, Washington Seattle Cancer Care Alliance Recruiting Seattle, Washington, United States Less <<
NCT03464201 Ovarian Cancer Phase 2 Recruiting March 2020 Spain ... More >> Hospital de Mar Recruiting Barcelona, Spain Hospital Reina Sofia Recruiting Córdoba, Spain Hospital Madrid Sanchinarro (CIOCC) Recruiting Madrid, Spain Contact: Garcia-Donas, MD    +34 91 756 79 84    jgarciadonas@gmail.com    Hospital Universitario La Paz Recruiting Madrid, Spain Hospital Son Llatzer Recruiting Palma De Mallorca, Spain Hospital de Navarra Recruiting Pamplona, Spain Complejo Hospitalario Universitario de Santiago Recruiting Santiago De Compostela, Spain Hospital La Fe Not yet recruiting Valencia, Spain Less <<
NCT02441517 Metastatic Castration Resistan... More >>t Prostate Cancer Less << PHASE4 TERMINATED 2017-03-15 Site US10003, Evanston, Illino... More >>is, 60201, United States|Site US10006, Worcester, Massachusetts, 01605, United States|Site US10004, New York, New York, 10029, United States|Site US10001, Charleston, South Carolina, 29425, United States|Site US10002, Myrtle Beach, South Carolina, 29572, United States Less <<
NCT02929576 Breast Cancer Phase 3 Withdrawn(Further understandin... More >>g about the role of androgen signaling in TNBC was required) Less << - United States, Kansas ... More >> Topeka, Kansas, United States, 66606 United States, Louisiana Metairie, Louisiana, United States, 70006 United States, New York Bronx, New York, United States, 10469 United States, Texas Houston, Texas, United States, 77030 United States, Washington Tacoma, Washington, United States, 98405 Wenatchee, Washington, United States, 98801 Less <<
NCT02960022 Prostate Cancer Phase 2 Recruiting July 2021 -
NCT02288936 Hormone-refractory Prostate Ca... More >>ncer Less << PHASE2 COMPLETED 2019-07-22 Hospital Universitari Germans ... More >>Trias I Pujol de Badalona, Badalona, Barcelona, 08916, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Islas Baleares, 07120, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, 08036, Spain|Hospital Parc Taulí, Barcelona, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, 14004, Spain|Complejo Asistencial Universitario de Leon, León, 24080, Spain|Hospital Universitario Lucus Augusti, Lugo, 27003, Spain|Hospital Ramón Y Cajal, Madrid, 28034, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital General Universitario J.M. Morales Meseguer, Murcia, 30008, Spain|Complejo Hospitalario de Especialidades Virgen de La Victoria, Málaga, 29010, Spain|Complexo Hospitalario Universitario de Ourense, Ourense, 32005, Spain|Complejo Hospitalario Regional Virgen Del Rocio, Sevilla, 41013, Spain|Fundación Instituto Valenciano de Oncologia, Valencia, 46009, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain Less <<
NCT03016312 Prostatic Neoplasms, Castratio... More >>n-Resistant Less << Phase 3 Active, not recruiting July 9, 2022 -
NCT03297385 Prostate Cancer|DNA|Androgen R... More >>eceptor Abnormal Less << PHASE2 COMPLETED 2017-04-01 -
NCT03123978 Metastatic Prostate Carcinoma ... More >> Recurrent Prostate Carcinoma Stage IV Prostate Cancer Less << Phase 1 Recruiting January 2021 United States, California ... More >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Chong-Xian Pan    916-734-3771    cxpan@ucdavis.edu    Principal Investigator: Chong-Xian Pan Less <<
NCT01911741 Healthy Subjects|Castration Re... More >>sistant Prostate Cancer (CRPC)|Relative Bioavailability|MDV3100 Less << PHASE1 COMPLETED 2025-03-13 Parexel International GmbH, Be... More >>rlin, 14050, Germany Less <<
NCT02441517 Metastatic Castration Resistan... More >>t Prostate Cancer Less << PHASE4 TERMINATED 2017-03-15 Site US10003, Evanston, Illino... More >>is, 60201, United States|Site US10006, Worcester, Massachusetts, 01605, United States|Site US10004, New York, New York, 10029, United States|Site US10001, Charleston, South Carolina, 29425, United States|Site US10002, Myrtle Beach, South Carolina, 29572, United States Less <<
NCT02922218 - Recruiting December 2020 Spain ... More >> Hospital Arquitecto Marcide Recruiting Ferrol, A Coruña, Spain, 15405 Contact: Javier Afonso, MD    +34981334000    Franciso.Javier.Afonso.Afonso@sergas.es    Hospital Universitario de Santiago Recruiting Santiago de Compostela, A Coruña, Spain, 15706 Contact: Urbano Anido, MD    +34981950000    urbanoanido@gmail.com    ICO L'Hospitalet Recruiting L'Hospitalet de Llobregat, Barcelona, Spain, 08907 Contact: Josep M. Piulats, MD    +34932607780    jmpiulats@iconcologia.net    Hospital Althaia Manresa Recruiting Manresa, Barcelona, Spain, 08243 Contact: Montserrat Domenech, MD    +34938759300 ext 3309    mdomenech@althaia.cat    Hospital de Especialidades de Jerez de la Frontera Recruiting Jerez de la Frontera, Cádiz, Spain, 11407 Contact: Ruth Viciana, MD    +34956032075    ruthvician@gmail.com    Hospital Costa del Sol Recruiting Marbella, Málaga, Spain, 29603 Contact: Rosa Villatoro, MD    +34951976470    villatororoldan@gmail.com    Complejo Hospitalario de Navarra Recruiting Pamplona, Navarra, Spain, 31008 Contact: Nuria Lainez, MD    +34948255400 ext 5870    nuria.lainez.milagro@cfnavarra.es    Hospital Universitario de Canarias Recruiting La Laguna, Tenerife, Spain, 38320 Contact: Rosa Delia Garcia, MD    +34922678204    rdgmarrero@gmail.com    Fundacion Centro Oncologico de Galicia Recruiting A Coruna, Spain, 15009 Contact: Ana Medina, MD    +34981287499 ext 174    ana.medina@cog.es    Hospital Universitario Vall D'Hebron Recruiting Barcelona, Spain, 08035 Contact: Rafael Morales, MD    +34932746000 ext 4695    rafael.morales.barrera@gmail.com    Hospital de Burgos Recruiting Burgos, Spain, 09006 Contact: Guillermo Crespo, MD    +34947281978    rescribano@seom.org    Contact: Ricardo Sanchez, MD    +34947281978    rescribano@seom.org    Hospital de Ciudad Real Recruiting Ciudad Real, Spain, 13005 Contact: Jose Carlos Villa, MD    +34926278000 ext 77137    jvillaguzman1@yahoo.es    Hospital Universitario Reina Sofia Recruiting Cordoba, Spain, 14004 Contact: Maria Jose Mendez, MD    +34957011147    mjosemv@yahoo.es    Hospital Universitario Virgen de las Nieves Recruiting Granada, Spain, 18014 Contact: Raquel Luque, MD    +34958020000    rluquecaro@gmail.com    Hospital Universitario de Guadalajara Recruiting Guadalajara, Spain, 19002 Contact: Javier Casinello, MD    +34949209200    jacaes@sescam.jccm.es    Hospital Universitario Gregorio Maranon Recruiting Madrid, Spain, 28007 Contact: Jose Angel Arranz, MD    +34914269070    jarranz@oncomed.gmail.com    Coordination PROCURE-Centro Nacional de Investigaciones Oncologicas Recruiting Madrid, Spain, 28029 Contact: Nuria Romero, MD    347328000 ext 2951    nromerol@cnio.es    Contact: Berta Nasarre, PhD       bnasarre@cnio.es    Sub-Investigator: Leticia Rivera, CRA senior          Sub-Investigator: Gala Grau, PhD          Sub-Investigator: Maria Isabel Pacheco, Technician          Sub-Investigator: Teresa Garces, Technician          Hospital Universitario Clinico San Carlos Recruiting Madrid, Spain, 28040 Contact: Javier Puente, MD    +34913303000 ext 7332    docjavip@yahoo.es    Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 Contact: Daniel Castellanos, MD    +34913908339    cdanicas@hotmail.com    Centro Integral Oncologico Clara Campal Recruiting Madrid, Spain, 28050 Contact: Elena Castro, MD    +34917328000 ext 2950    ecastro@hmhospitales.com    Hospital Regional Universitario Virgen de la Victoria Recruiting Malaga, Spain, 29010 Contact: Maria Isabel Medina, MD    +34951291425    msaez.med@gmail.com    Hospital Morales Messeguer Recruiting Murcia, Spain, 30008 Contact: Enrique Gonzalez, MD    +34968360900 ext 3807    engonbil@um.es    Hospital Virgen de la Victoria Recruiting Málaga, Spain, 29010 Contact: David Olmos, MD    34 91 732 8000 ext 2950    dolmos@cnio.es    Contact: Gala Grau, PhD    34697959726    gala.gala.grau.eecc@gmail.com    Hospital Son Espases Recruiting Palma de Mallorca, Spain, 07120 Contact: Aranzazu Gonzalez, MD    +34871206130 ext 76130    aranzazu.gonzalezdealba@ssib.es    Complejo Hospitalario de Pontevedra Recruiting Pontevedra, Spain, 36002 Contact: Cristina Azpitarte, MD    +34 986800004    crisazpi@hotmail.com    Hospital Universitario La Fe Recruiting Valencia, Spain, 46026 Contact: David Lorente, MD    +34961244000    davlorente@hotmail.com Less <<
NCT03177187 Metastatic Castration Resistan... More >>t Prostate Cancer Less << Phase 1 Phase 2 Not yet recruiting December 2020 -
NCT02384382 Prostate Carcinoma Metastatic ... More >>to the Bone|Castration Resistant Prostate Cancer Less << PHASE2 COMPLETED 2019-05-03 Karmanos Cancer Institute, Det... More >>roit, Michigan, 48201, United States|Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, 48334, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|Wimr Pet/Ct, Madison, Wisconsin, 53763, United States|UW Clinical Sciences Center, Madison, Wisconsin, 53792, United States Less <<
NCT02125084 Prostate Cancer Phase 1 Active, not recruiting January 2019 United States, Florida ... More >> Florida Cancer Specialists Fort Myers, Florida, United States, 33916 Florida Cancer Center Saint Petersburg, Florida, United States, 33705 United States, Ohio Oncology Hematology Care Inc. Cincinnati, Ohio, United States, 45242 United States, Tennessee Tennessee Oncology Chattanooga, Tennessee, United States, 37404 Tennessee Oncology PLLC Nashville, Tennessee, United States, 37203 Less <<
NCT02319837 Hormone Sensitive Prostate Can... More >>cer Prostate Cancer Cancer of the Prostate Less << Phase 3 Active, not recruiting July 31, 2023 -
NCT02003924 - Active, not recruiting - -
NCT03336983 Prostate Cancer ... More >> Bone Metastases Less << Phase 2 Recruiting December 1, 2023 Italy ... More >> Azienda Ospedaliera Spedali Civili di Brescia Recruiting Brescia, Italy, 25123 Less <<
NCT02495974 - Active, not recruiting March 2019 -
NCT02138799 Drug-Drug Interaction (DDI) ... More >> Healthy Subjects Pharmacokinetics of Enzalutamide Less << Phase 1 Completed - Germany ... More >> Parexel International GmbH Berlin, Germany, 14050 Less <<
NCT02116582 Metastatic Castration-Resistan... More >>t Prostate Cancer Less << PHASE4 COMPLETED 2017-09-29 Site BE32001, Brussels, Flemis... More >>h Brabant, 1200, Belgium|Site BE32004, Gent, 9000, Belgium|Site BE32007, Hasselt, 3500, Belgium|Site BE32003, Kortrijk, 8500, Belgium|Site BE32002, Liege, 4000, Belgium|Site FR33015, Angers cedex 02, 49055, France|Site FR33009, Caen Cedex 05, 14076, France|Site FR33010, Creteil cedex, 94010, France|Site FR33014, Le Mans, 72015, France|Site FR33013, Lyon Cedex 3, 69003, France|Site FR33003, Marseille CEDEX 9, 13273, France|Site FR33008, Nantes Saint Herblain Cedex, 44805, France|Site FR33002, Nimes, 30029, France|Site FR33001, Paris cedex 15, 75908, France|Site FR33011, Paris, 75005, France|Site FR33007, Rennes, 35042, France|Site FR33005, Suresnes, 92151, France|Site FR33012, Villejiuf, 94805, France|Site DE49005, Nuertingen, Baden-Wuerttemberg, 72622, Germany|Site DE49015, Bergisch Gladbach, Northwest, 51427, Germany|Site DE49017, Duisburg, NRW, 47179, Germany|Site DE49014, Berlin, 10247, Germany|Site DE49003, Berlin, 12200, Germany|Site DE49009, Bonn, 53111, Germany|Site DE49010, Dresden, 01307, Germany|Site DE49016, Duesseldorf, 40225, Germany|Site DE49004, Goettingen, 37075, Germany|Site DE49001, Hamburg, 22081, Germany|Site DE49008, Hamburg, 22399, Germany|Site DE49007, Hannover, 30625, Germany|Site DE49002, Heidelberg, 69120, Germany|Site DE49012, Munster, 48149, Germany|Site DE49006, Tubingen, 72076, Germany|Site ES34004, Santiago de Compostela, A Coruna, 15706, Spain|Site ES34009, Badalona, 8916, Spain|Site ES34011, Barcelona, 08003, Spain|Site ES34006, Barcelona, 08025, Spain|Site ES34008, Barcelona, 08035, Spain|Site ES34001, Madrid, 28007, Spain|Site ES34003, Madrid, 28034, Spain|Site ES34002, Madrid, 28040, Spain|Site ES34010, Madrid, 28044, Spain|Site GB44001, Sutton, Surrey, SM2 5PT, United Kingdom|Site GB44004, Birmingham, B15 2TT, United Kingdom|Site GB44009, Brighton, BN2 5BE, United Kingdom|Site GB44002, Glasgow, G12 0YN, United Kingdom|Site GB44007, London, SE1 9RT, United Kingdom|Site GB44003, Northwood, Middlesex, HA6 2RN, United Kingdom|Site GB44010, Plymouth, PL6 8DH, United Kingdom|Site GB44006, Withington, M204BX, United Kingdom Less <<
NCT02116582 Metastatic Castration-Resistan... More >>t Prostate Cancer Less << PHASE4 COMPLETED 2017-09-29 Site BE32001, Brussels, Flemis... More >>h Brabant, 1200, Belgium|Site BE32004, Gent, 9000, Belgium|Site BE32007, Hasselt, 3500, Belgium|Site BE32003, Kortrijk, 8500, Belgium|Site BE32002, Liege, 4000, Belgium|Site FR33015, Angers cedex 02, 49055, France|Site FR33009, Caen Cedex 05, 14076, France|Site FR33010, Creteil cedex, 94010, France|Site FR33014, Le Mans, 72015, France|Site FR33013, Lyon Cedex 3, 69003, France|Site FR33003, Marseille CEDEX 9, 13273, France|Site FR33008, Nantes Saint Herblain Cedex, 44805, France|Site FR33002, Nimes, 30029, France|Site FR33001, Paris cedex 15, 75908, France|Site FR33011, Paris, 75005, France|Site FR33007, Rennes, 35042, France|Site FR33005, Suresnes, 92151, France|Site FR33012, Villejiuf, 94805, France|Site DE49005, Nuertingen, Baden-Wuerttemberg, 72622, Germany|Site DE49015, Bergisch Gladbach, Northwest, 51427, Germany|Site DE49017, Duisburg, NRW, 47179, Germany|Site DE49014, Berlin, 10247, Germany|Site DE49003, Berlin, 12200, Germany|Site DE49009, Bonn, 53111, Germany|Site DE49010, Dresden, 01307, Germany|Site DE49016, Duesseldorf, 40225, Germany|Site DE49004, Goettingen, 37075, Germany|Site DE49001, Hamburg, 22081, Germany|Site DE49008, Hamburg, 22399, Germany|Site DE49007, Hannover, 30625, Germany|Site DE49002, Heidelberg, 69120, Germany|Site DE49012, Munster, 48149, Germany|Site DE49006, Tubingen, 72076, Germany|Site ES34004, Santiago de Compostela, A Coruna, 15706, Spain|Site ES34009, Badalona, 8916, Spain|Site ES34011, Barcelona, 08003, Spain|Site ES34006, Barcelona, 08025, Spain|Site ES34008, Barcelona, 08035, Spain|Site ES34001, Madrid, 28007, Spain|Site ES34003, Madrid, 28034, Spain|Site ES34002, Madrid, 28040, Spain|Site ES34010, Madrid, 28044, Spain|Site GB44001, Sutton, Surrey, SM2 5PT, United Kingdom|Site GB44004, Birmingham, B15 2TT, United Kingdom|Site GB44009, Brighton, BN2 5BE, United Kingdom|Site GB44002, Glasgow, G12 0YN, United Kingdom|Site GB44007, London, SE1 9RT, United Kingdom|Site GB44003, Northwood, Middlesex, HA6 2RN, United Kingdom|Site GB44010, Plymouth, PL6 8DH, United Kingdom|Site GB44006, Withington, M204BX, United Kingdom Less <<
NCT02028988 Intermediate Risk Prostate Can... More >>cer Less << Phase 2 Active, not recruiting June 2021 United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT02528643 - Active, not recruiting - -
NCT02528643 Advanced Hepatocellular Carcin... More >>oma Less << Phase 2 Active, not recruiting May 2019 -
NCT02207504 Castration-resistant Prostate ... More >>Cancer Less << Phase 1 Active, not recruiting December 2018 United States, Massachusetts ... More >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT02124668 Castration-Resistant Prostate ... More >>Cancer|Prostate Cancer Less << PHASE2 COMPLETED 2017-05-25 Site GE99503, Tbilisi, 0144, G... More >>eorgia|Site GE99502, Tbilisi, 0159, Georgia|Site RU70002, Moscow, 115478, Russian Federation|Site RU70003, Moscow, 125284, Russian Federation Less <<
NCT02684227 Endometrial Cancer Phase 2 Recruiting August 2019 United States, Texas ... More >> MD Anderson Cancer Center - Memorial City Regional Care Center Recruiting Houston, Texas, United States, 77024 Contact: Appointments    713-358-5300       Principal Investigator: Nicole Fleming, MD          University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: MD Anderson Health Information Specialist    877-632-6789       The Woman's Hospital of Houston Recruiting Houston, Texas, United States, 77054 MD Anderson Cancer Center - Katy Regional Care Center Recruiting Houston, Texas, United States, 77094 Contact: Appointments    713-745-9940       Principal Investigator: Nicole Fleming, MD          MD Anderson Cancer Center - Bay Area Regional Care Center Recruiting Nassau Bay, Texas, United States, 77058 Contact: Appointments    713-745-9940       Principal Investigator: Nicole Fleming, MD          MD Anderson Cancer Center - Sugar Land Regional Care Center Recruiting Sugar Land, Texas, United States, 77478 Contact: Appointments    713-745-9940       Principal Investigator: Nicole Fleming, MD          MD Anderson Cancer Center - The Woodlands Recruiting The Woodlands, Texas, United States, 77384 Contact: Appointments    713-745-9940       Principal Investigator: Nicole Fleming, MD Less <<
NCT01942837 Metastatic Castration-resistan... More >>t Prostate Cancer Less << PHASE2 COMPLETED 2022-09-30 Brigham and Women's Hospital, ... More >>Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|South Shore Hospital, Weymouth, Massachusetts, 02190, United States|University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington, 98195, United States Less <<
NCT03641560 Metastatic Castration Resistan... More >>t Prostate Cancer Less << Phase 4 Recruiting May 2020 India ... More >> Site IN00002 Recruiting Ahmedabad, India Site IN00004 Recruiting Hubli, India Site IN00008 Recruiting Kolkata, India Site IN00003 Recruiting Nashik, India Site IN00007 Recruiting Nashik, India Site IN00001 Recruiting Pune, India Less <<
NCT02138162 Severe Hepatic Impairment ... More >> Normal Hepatic Function Less << Phase 1 Completed - Bulgaria ... More >> Comac Medical Ltd. Sofia, Bulgaria, 1612 Less <<
NCT03103724 Carcinoma Prostate Phase 2 Recruiting March 16, 2019 Italy ... More >> Elena Verzoni Recruiting Milan, Italy, 20133 Contact: Elena Verzoni, MD    +390223904449    Elena.verzoni@istitutotumori.mi.it    Contact: Rosanna Montone, Dr.ssa    +390223903817    Rosanna.montone@istitutotumori.mi.it Less <<
NCT03196388 Prostate Carcinoma PHASE2 UNKNOWN 2025-12-18 Hospital Ramón y Cajal, Madrid... More >>, Spain Less <<
NCT03674814 Prostate Cancer Phase 1 Recruiting March 10, 2020 United States, Illinois ... More >> University Of Chicago Medicine Comprehensive Cancer Center Recruiting Chicago, Illinois, United States, 60637 Contact: Julie Gruszczynski    773-834-9961    Jgruszczynski@medicine.bsd.uchicago.edu    Principal Investigator: Russell Szmulewitz, MD Less <<
NCT01902251 Prostate Cancer ... More >> Pharmacokinetics of Enzalutamide Less << Phase 1 Completed - United States, Colorado ... More >> University of Colorado - Anschutz Medical Campus Denver, Colorado, United States, 80045 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Pennsylvania University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15232 United States, Texas South Texas Accelerated Research Therapeutics San Antonio, Texas, United States, 78229 Less <<
NCT02500901 Metastatic Prostate Cancer Phase 1 Terminated(Suspended by funder... More >>) Less << - United States, Massachusetts ... More >> Tufts Medical Center Boston, Massachusetts, United States, 02111 Less <<
NCT03207529 Malignant Neoplasm of Breast Phase 1 Not yet recruiting January 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations       mskaruturi@mdanderson.org Less <<
NCT03328364 - Completed - Sweden ... More >> Site SE46001 Malmo, Sweden Less <<
NCT03124615 Prostate Cancer PHASE2 UNKNOWN 2025-06-21 Macquarie University, North Ry... More >>de, New South Wales, 2109, Australia Less <<
NCT02953860 Breast Cancer Phase 2 Recruiting November 2021 United States, Colorado ... More >> University of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Tiffany Colvin    303-848-0664    TIFFANY.COLVIN@UCDENVER.EDU    Principal Investigator: Anthony D Elias, MD          Lone Tree Medical Center Recruiting Lone Tree, Colorado, United States, 80124 Contact: Lisa Lopez       lisa.lopez@ucdenver.edu    Principal Investigator: Regina Brown, MD          United States, Tennessee West Cancer Center Recruiting Germantown, Tennessee, United States, 38138 Contact: Julie Ryder    901-683-0055    jryder@westclinic.com    Principal Investigator: Gregory Vidal, MD Less <<
NCT01927627 Adenocarcinoma of the Prostate Phase 2 Active, not recruiting March 2019 United States, Ohio ... More >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less <<
NCT02911467 Prostate Cancer Phase 1 Recruiting December 30, 2020 United States, California ... More >> University of California, San Francisco Recruiting San Francisco, California, United States, 94158 Contact: Rahul Aggarwal, MD    415-353-9278    Rahul.Aggarwal@ucsf.edu    Contact: Paula Dutton, BS    415-885-7871    Paula.Dutton@ucsf.edu Less <<
NCT02920229 68Ga-PSMA HBED-PET/CT ... More >> Prostate Cancer Less << Not Applicable Recruiting November 2018 Italy ... More >> Irst Irccs Recruiting Meldola, FC, Italy, 47014 Contact: Federica Matteucci, MD    +390543739100    federica.matteucci@irst.emr.it    Principal Investigator: Federica Matteucci, MD          Sub-Investigator: Ugo De Giorgi, MD Less <<
NCT03170960 Urothelial Carcinoma ... More >> Renal Cell Carcinoma Non-Small Cell Lung Cancer Castration-resistant Prostate Cancer Triple Negative Breast Cancer Ovarian Cancer Endometrial Cancer Hepatocellular Carcinoma Gastric Cancer Gastroesophageal Junction Adenocarcinoma Colorectal Cancer Head and Neck Cancer Differentiated Thyroid Cancer Less << Phase 1 Phase 2 Recruiting December 2020 -
NCT02813226 Prostate Cancer Not Applicable Active, not recruiting December 2020 Canada, Ontario ... More >> Juravinski Hospital and Cancer Centre Hamilton, Ontario, Canada London Health Sciences Centre London, Ontario, Canada Sunnybrook-Odette Cancer Centre Toronto, Ontario, Canada Less <<
NCT03075735 - Active, not recruiting December 15, 2018 -
NCT02456571 - Recruiting June 2019 United States, North Carolina ... More >> Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Monika Anand, PhD    919-681-8838    monika.anand@duke.edu Less <<
NCT02008058 - Active, not recruiting December 2021 United States, Maryland ... More >> Johns Hopkins University Baltimore, Maryland, United States, 21231 United States, North Carolina Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Washington University of Washington Seattle, Washington, United States, 98109 Less <<
NCT02398526 - Active, not recruiting September 30, 2023 Germany ... More >> Multiple Locations, Germany Less <<
NCT02729103 - Completed - United States, New Jersey ... More >> Whippany, New Jersey, United States Less <<
NCT02012920 Castration-resistant Prostate ... More >>Cancer CRPC Less << Phase 2 Active, not recruiting December 2018 -
NCT02202447 Prostate Cancer Phase 1 Active, not recruiting October 2018 United States, Arizona ... More >> Scottsdale Healthcare Clinical Trials at the Virginia G. Piper Cancer Center Scottsdale, Arizona, United States, 85258 United States, Connecticut Yale Cancer Center New Haven, Connecticut, United States, 06520 United States, Louisiana Tulane Cancer Center New Orleans, Louisiana, United States, 70112 United States, Nevada Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States, 89169 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10017 United States, Texas South Texas Accelerated Research Therapeutics San Antonio, Texas, United States, 78229 Less <<
NCT02091531 Metastatic Castration-Resistan... More >>t Prostate Cancer Less << Phase 2 Completed - United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT00268476 Prostate Cancer Phase 2 Phase 3 Recruiting September 2024 -
NCT03690141 Castrate-resistant Prostate Ca... More >>ncer (CRPC) Less << Phase 2 Recruiting April 2022 United States, Connecticut ... More >> Yale Cancer Center Not yet recruiting New Haven, Connecticut, United States, 06510 Principal Investigator: Daniel Petrylak, M.D.          United States, Illinois Northwestern University Not yet recruiting Chicago, Illinois, United States, 60611 Contact: Lela Lartey    312-695-1377    emanuela.lartey@northwestern.edu    Principal Investigator: Maha Hussain, M.D.          United States, Maryland Kimmel Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21205 Contact: Rehab Abdallah    443-253-7021    rabdall1@jhmi.edu    Principal Investigator: Michael Carducci, M.D.          United States, Michigan Karmanos Cancer Institute Not yet recruiting Detroit, Michigan, United States, 48201 Principal Investigator: Elisabeth Heath, M.D.          United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Andrew Atkocius    314-747-1343    a.atkocius@wustl.edu    Principal Investigator: Joel Picus, M.D.          United States, Nevada Comprehensive Cancer Centers of Nevada Recruiting Las Vegas, Nevada, United States, 89169 Principal Investigator: Nicholas Vogelzang, M.D.          United States, Ohio The Urology Group Recruiting Cincinnati, Ohio, United States, 45212 Contact: Bill Corbett    513-841-7555    wcorbett@urologygroup.com    Principal Investigator: Marc Pliskin, M.D.          United States, Pennsylvania Lancaster Urology Recruiting Lancaster, Pennsylvania, United States, 17604 Contact: Dawn Stern    717-431-2285    Dawns@lancuro.com    Principal Investigator: Paul Sieber, M.D.          United States, South Carolina Carolina Urologic Research Center Recruiting Myrtle Beach, South Carolina, United States, 29572 Contact: Laura Prince    843-839-1679    lprince@curcmb.com    Principal Investigator: Neal Shore, M.D.          United States, Washington University of Washington Not yet recruiting Seattle, Washington, United States, 89109 Principal Investigator: Celestia Higano, M.D. Less <<
NCT02494921 Prostate Cancer Phase 1 Phase 2 Recruiting December 2019 United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center Active, not recruiting San Francisco, California, United States, 94115 United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Benedito A. Carneiro, MD    312-472-1234       Principal Investigator: Benedito A. Carneiro, MD          United States, Michigan University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: David Smith, MD    800-865-1125       Principal Investigator: David Smith, MD Less <<
NCT03763253 Prostate Cancer ... More >> Metastatic Prostate Cancer Less << Phase 2 Not yet recruiting March 1, 2024 United Kingdom ... More >> Wirral University Teaching Hospital Not yet recruiting Birkenhead, United Kingdom, CH49 5PE Contact: Manal Kumar, MBBS MS MSh FRCS ED          Principal Investigator: Manal Kumar, MBBS MS MSh FRCS ED          Broomfield Hospital Not yet recruiting Chelmsford, United Kingdom, CM1 7ET Contact: Casey Rowan, FRCS (Urol)          Principal Investigator: Casey Rowan, FRCS (Urol)          Ashford and St Peters Not yet recruiting Chertsey, United Kingdom, KT16 0PZ Contact: Nimalan Arumainayagam, FRCS (Urol)          Principal Investigator: Nimalan Arumainayagam, FRCS (Urol)          Royal Devon and Exeter NHS Trust Not yet recruiting Exeter, United Kingdom, EX2 5DW Contact: John McGrath, BMedSci BMBS FRCS          Principal Investigator: John McGrath, BMedSci BMBS FRCS          Wycombe General Hospital Not yet recruiting High Wycombe, United Kingdom, HP11 2TT Contact: Neil Haldel, MBBS MB FRCS (Urol)          Principal Investigator: Neil Haldel, MBBS MB FRCS (Urol)          West Middlesex University Hospital Not yet recruiting Isleworth, United Kingdom, TW7 6AF Contact: Mathias Winkler, MBBS BSc MD FRCS (Urol)          Principal Investigator: Mathias Winkler, MBBS BSc MD FRCS (Urol          Cambridge Queen Elizabeth hospital, Kings Lynn Not yet recruiting King's Lynn, United Kingdom, PE30 4ET Contact: Gail Horan, MRCPI, FRCR          Principal Investigator: Gail Horan, MRCPI, FRCR          Guys and St Thomas Hospital Not yet recruiting London, United Kingdom, SE1 7EH Contact: Paul Cathcart, FRCS (Urol)          Principal Investigator: Paul Cathcart, FRCS (Urol)          St George's Hospital, St. George's University Hospitals NHS Foundation Trust Not yet recruiting London, United Kingdom, SW17 0QT Contact: Hasan Qazi, FRCS (Urol)          Principal Investigator: Hasan Qazi, FRCS (Urol)          Imperial College Healthcare NHS Trust Not yet recruiting London, United Kingdom, W6 8RF Contact: Hashim U Ahmed, BM, BCh (Oxon), BA, PhD, FRCS          Principal Investigator: Hashim U Ahmed, BM, BCh (Oxon), BA, PhD, FRCS          Sub-Investigator: Taimur T Shah, MBBS, BSc (Hons), MRCS          Sub-Investigator: Martin J Connor, MBBS, BSc (Hons), MSc, MRCS          Sub-Investigator: Mathias Winkler, MD, FRCS (Urol)          Sub-Investigator: John Staffurth, MD, FRCP, FRCR          Sub-Investigator: Alison Falconer, MA, MRCP, FRCR          Sub-Investigator: Suraiya Dubash, MBBS, BSc, MRCP, FRCR          London North West University Healthcare (Northwick Park) Not yet recruiting London, United Kingdom Contact: Giles Hellawell, MA BM BCH FRCS          Principal Investigator: Giles Hellawell, MA BM BCH FRCS          Newcastle Hospitals NHS trust (Freeman Hospital) Not yet recruiting Newcastle, United Kingdom, NE7 7DM Contact: Rakesh Heer, PhD FRCS(Urol)          Principal Investigator: Rakesh Heer, PhD FRCS(Urol)          Glan Clwyd Hospital (Betsi Cadwaladr University Health Board) Not yet recruiting Rhyl, United Kingdom, LL18 5UJ Contact: Kingsley Ekwueme, FRCS (Urol)          Principal Investigator: Kingsley Ekwueme, FRCS (Urol)          Southampton General Hospital Not yet recruiting Southampton, United Kingdom, SO16 6YD Contact: Tim Dudderidge, FRCS (Urol)          Principal Investigator: Tim Dudderidge, FRCS (Urol)          Lister Hospital Not yet recruiting Stevenage, United Kingdom, SG1 4AB Contact: Nikhil Vasdev, FRCS (Urol)          Principal Investigator: Nikhil Vasdev, FRCS (Urol)          Sunderland Royal hospital Not yet recruiting Sunderland, United Kingdom, SR4 7TP Contact: Stuart McCracken, FRCS (Urol)          Principal Investigator: Stuart McCraken, FRCS (Urol)          Wrexham Maelor Hospital (Betsi Cadwaladr University Health Board) Not yet recruiting Wrexham, United Kingdom, LL13 7TD Contact: Iqbal Shergill, FRCS (Urol)          Principal Investigator: Iqbal Shergill, FRCS (Urol) Less <<
NCT02432001 - Recruiting December 2018 United States, California ... More >> University of California, Davis Recruiting Davis, California, United States, 95616 Contact: Primo Lara, MD          University of California, Los Angeles Recruiting Los Angeles, California, United States, 90095 Contact: Matthew Rettig, MD          UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94115 Contact: Paula Dutton    415-885-7871    Paula.Dutton@ucsf.edu    United States, Oregon Oregon Health & Science University Recruiting Portland, Oregon, United States, 97239 Contact: Tomasz Beer, MD          Canada University of British Columbia Recruiting Vancouver, Canada Contact: Kim Chi, MD Less <<
NCT03551782 Castration-Resistant Prostatic... More >> Neoplasms Less << Phase 1 Recruiting January 29, 2021 -
NCT02606123 Prostatic Neoplasms ... More >> Genital Neoplasms, Male Genital Diseases, Male Prostatic Diseases Less << Phase 1 Phase 2 Terminated(At end of Phase 1 e... More >>xcessive high pill burden (18 capsules/day)) Less << - United States, Arizona ... More >> Scottsdale Healthcare Hospitals DBA HonorHealth Scottsdale, Arizona, United States, 85258 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 Canada, British Columbia British Columbia Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Less <<
NCT03685591 Hormone Receptor Positive Adva... More >>nced Breast Cancer Metastatic Breast Cancer Human Epidermal Receptor 2 Negative Advanced Breast Cancer Castration Resistant Prostate Cancer Less << Phase 1 Recruiting August 24, 2023 United States, Texas ... More >> The University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030-4009 The University of Texas - MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 NEXT Oncology Recruiting San Antonio, Texas, United States, 78240 Less <<
NCT02826772 Metastatic Castrate Resistant ... More >>Prostate Cancer (mCRPC) Less << Phase 1 Phase 2 Recruiting December 2018 United States, Maryland ... More >> Chesapeake Urology Research Associates Recruiting Towson, Maryland, United States, 21204 Contact: Heather Thomas, CCRC    443-471-5742    hthomas@cua.md    Contact: Heidi Miller, BScN    514.463.8837    hmiller@accelovance.com    Principal Investigator: Richard Levin, MD          United States, Nebraska G U Research Network Recruiting Omaha, Nebraska, United States, 68130 Contact: Tony Romero, MS, CCRC    402-697-2229    tromero@gucancer.com    Contact: Heidi Miller, BScN    514.463.8837    hmiller@accelovance.com    Principal Investigator: Luke T Nordquist, MD          United States, Nevada Comprehensive Cancer Centers of Nevada Recruiting Las Vegas, Nevada, United States, 89169 Contact: Khin Win, MBA, MBBS    702-952-3834    khin.win@usoncology.com    Contact: Heidi Miller, BScN    514.463.8837    hmiller@accelovance.com    Principal Investigator: Nicholas Vogelzang, MD          United States, New Jersey Rutgers University Recruiting New Brunswick, New Jersey, United States, 08901 Contact: Tracie Saunders, RN, MS, OCN, CCRC    732-235-8861    tracie.saunders@cinj.rutgers.edu    Contact: Heidi Miller, BScN    514.463.8837    hmiller@accelovance.com    Principal Investigator: Mark N Stein, MD          United States, New York North Shore Hematology Oncology Associates Recruiting East Setauket, New York, United States, 11733 Contact: Don Marx, MBA, MS, RT    631-675-5143    dmarx@nycancer.com    Contact: Heidi Miller, BScN    514.463.8837    hmiller@accelovance.com    Principal Investigator: Jeffrey L Vacirca, MD, FACP          United States, Ohio Gabrail Cancer Center Research Recruiting Canton, Ohio, United States, 44718 Contact: Carrie Smith, RN    484-998-8315    csmith@gabrailcancercenter.com    Contact: Heidi Miller, BScN    514.463.8837    hmiller@accelovance.com    Principal Investigator: Nashat Gabrail, MD Less <<
NCT03526562 Prostatic Neoplasms ... More >> Exercise Castration-resistant Prostate Cancer Physical Activity Less << Not Applicable Recruiting October 2018 Belgium ... More >> University Hospital ghent Recruiting Ghent, Oost-Vlaanderen, Belgium, 9000 Contact: Renée Bultijnck, Msc    932 3320342    renee.bultijnck@ugent.be    Contact: Piet Ost, MD, PhD Less <<
NCT02856100 - Unknown December 2018 United States, Maryland ... More >> Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Ghedem Solomon, MS    410-614-2789    gsolomo6@jhmi.edu    Contact: Akimosa Jeffrey-Kwanisai, MBA    410-502-1040    ajeffre2@jhmi.edu Less <<
NCT03356912 Prostate Cancer ... More >> Castration-resistant Prostate Cancer Less << Phase 2 Enrolling by invitation May 4, 2021 Italy ... More >> University Federico II of Naples Naples, Italy Less <<
NCT03514836 Castration-resistant Prostate ... More >>Cancer Less << Phase 1 Phase 2 Recruiting April 2021 Czechia ... More >> Fakultní nemocnice v Motole Recruiting Praha, Czechia, 150 06 Less <<
NCT03050866 Circulating Tumor Cell ... More >> Metastatic Prostate Cancer Less << Phase 2 Recruiting February 2020 Netherlands ... More >> Reinier de Graaf Groep Recruiting Delft, Netherlands Contact: A.C.M. Van de Luijtgaarden, MD          Principal Investigator: A.C.M. Van de Luijtgaarden, MD          Medisch Centrum Haaglanden Recruiting Den Haag, Netherlands Contact: H. Helgason, MD          Principal Investigator: H Helgason, MD          Groene Hart Ziekenhuis Recruiting Gouda, Netherlands Contact: W. Van der Deure, MD          Principal Investigator: W Van der Deure, MD          Canisius Wilhelmina Ziekenhuis Recruiting Nijmegen, Netherlands Contact: R. Somford, MD          Principal Investigator: R. Somford, MD          Erasmus MC Recruiting Rotterdam, Netherlands Contact: Bodine Belderbos       caba.v7@erasmusmc.nl    Franciscus Gasthuis en Vlietland Recruiting Rotterdam, Netherlands Contact: Paul Hamberg          Maasstad Ziekenhuis Recruiting Rotterdam, Netherlands Contact: B. Haberkorn, MD          Principal Investigator: B. Haberkorn, MD          Tweesteden Ziekenhuid Recruiting Tilburg, Netherlands Contact: A. Coumou, MD          Principal Investigator: A Coumou, MD          Admiraal de Ruyter Ziekenhuis Recruiting Vlissingen, Netherlands Contact: H.K. Van Halteren, MD          Principal Investigator: H.K. Van Halteren, MD Less <<
NCT01695044 Prostate Cancer Phase 2 Completed - -
NCT01695044 - Completed - -
NCT03725761 Prostate Cancer Phase 2 Recruiting June 1, 2021 United States, California ... More >> UCSD Moores Cancer Center Not yet recruiting La Jolla, California, United States, 92093 Contact: Candance Winkler    858-822-5398    cmwinkler@ucsd.edu    Principal Investigator: Rana McKay, MD          United States, Michigan Wayne State University Barbara Ann Karmanos Cancer Institute Not yet recruiting Detroit, Michigan, United States, 48201 Contact: Brenda Dickow    313-576-9372    dickowb@karmanos.org    Principal Investigator: Elisabeth Heath, MD          United States, Minnesota University of Minnesota Masonic Cancer Center Not yet recruiting Minneapolis, Minnesota, United States, 55455 Contact: Shilpa Gupta    612-625-0571    guptash@umn.edu    Principal Investigator: Arpit Rao, MD          United States, New York Memorial Sloan-Kettering Cancer Center Not yet recruiting New York, New York, United States, 10065 Contact: Rebecca Green    646-888-1313    borsukr@mskcc.org    Principal Investigator: Susan Slovin, MD          Weill Cornell Medical College Not yet recruiting New York, New York, United States, 10065 Contact: Jyoti Sreekumar    646-962-9340    jys2004@med.cornell.edu    Principal Investigator: Himisha Beltran, MD          United States, Wisconsin University of Wisconsin Carbone Cancer Center Recruiting Madison, Wisconsin, United States, 53792 Contact: Mary Jane Staab    608-263-7107    mjs@medicine.wisc.edu    Principal Investigator: Christos Kyriakopoulos Less <<
NCT02621190 Prostatic Neoplasms Phase 2 Withdrawn(no approval) June 2019 Netherlands ... More >> Erasmus MC Cancer Institute Rotterdam, Netherlands, 3075 EA Less <<
NCT02512185 - Recruiting February 2019 Canada, Ontario ... More >> Juravinski Cancer Centre Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Sebastien Hotte, MD    905-387- 9711 ext 64605    sebastien.hotte@jcc.hhsc.ca    Kingston Health Sciences Centre -KGH Recruiting Kingston, Ontario, Canada, K7L 2V7 Contact: Carrie Lindsay    : 613-549-6666 ext 7231    Carrie.Lindsay@kingstonhsc.ca    Principal Investigator: Richard Gregg, MD., FRCPC          Odette Cancer Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Urban Emmenegger, MD    416-480-4928    urban.emmenegger@sunnybrook.ca    Sub-Investigator: Scott Berry, MD          Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Henriette Breunis    +1-416-946-4501 ext 3926    hbreunis@uhnresearch.ca    Principal Investigator: Shabbir Alibhai, MD          Sub-Investigator: Anthony Joshua, MD          Sub-Investigator: Aaron Hansen, MD Less <<
NCT02907372 Metastatic Castration-resistan... More >>t Prostate Cancer (CRPCa) Less << Not Applicable Recruiting November 2020 France ... More >> CHU Recruiting Amiens, France Contact: Mathieu BOONE, MD          Principal Investigator: Mathieu BOONE          centre François Baclesse Recruiting Caen, France Contact: Florence JOLY, PhD          Principal Investigator: Florence JOLY, PhD          Institut régional du Cancer de Montpellier (ICM) Recruiting Montpellier, France Contact: Amélie DARLIX, MD          Principal Investigator: Amélie DARLIX, MD          Chu Rouen Recruiting Rouen, France Contact: Sophie GOUERANT, MD          Principal Investigator: Sophie GOUERANT, MD          CHU Not yet recruiting Strasbourg, France Contact: Philippe BARTHELEMY, MD          Principal Investigator: Philippe BARTHELEMY, MD          IGR Not yet recruiting Villejuif, France Contact: Giulia BACIARELLO, PhD          Principal Investigator: Karim FIZAZI, PhD Less <<
NCT02903160 Prostate Cancer Phase 2 Recruiting October 2019 United States, New York ... More >> Mount Sinai Beth Israel Recruiting New York, New York, United States, 10011 Contact: Bobby Liaw, MD    212-604-6010    bobby.liaw@mountsinai.org    Principal Investigator: Bobby Liaw, MD          Mount Sinai West Withdrawn New York, New York, United States, 10019 Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10028 Contact: William Oh, MD    212-659-5549    william.oh@mssm.edu    Principal Investigator: William Oh, MD Less <<
NCT03236688 - Recruiting September 2018 United States, Connecticut ... More >> Yale University School of Medicine Recruiting New Haven, Connecticut, United States, 06520 Contact: Ken F Blount, Ph.D.    203-785-5927    ken.blount@yale.edu    Principal Investigator: Daniel Petrylak, MD Less <<
NCT04142060 Breast Cancer PHASE2 TERMINATED 2022-10-10 ICO Badalona, Badalona, Barcel... More >>ona, Spain|Institut Català d'Oncologia Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari Vall d' Hebrón, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario Fundación de Alcorcón, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, 46009, Spain Less <<
NCT03927391 Prostatic Neoplasms, Castratio... More >>n-Resistant Less << PHASE4 COMPLETED 2024-01-08 CWZ, Nijmegen, Netherlands|Rad... More >>boudumc, Nijmegen, Netherlands|Franciscus Gasthuis en Vlietland hospital, Rotterdam, Netherlands Less <<
NCT00510718 Prostate Cancer|Hormone Refrac... More >>tory Prostate Cancer Less << PHASE1 COMPLETED 2018-04-02 Dana-Farber Cancer Institute (... More >>DFCI), Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, 02215, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|MSKCC- Sidney Kimmel Center, New York, New York, 10065, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Investigational Pharmacy Services, Houston, Texas, 77030-4009, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030-4009, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|University of Washington Medical Center, Seattle, Washington, 98195, United States Less <<
NCT06015321 Prostatic Adenocarcinoma PHASE2 NOT_YET_RECRUITING 2026-04-30 Samsung Medical Center, Seoul,... More >> Korea, 06531, Korea, Republic of Less <<
NCT01284920 Prostate Cancer|Prostate Neopl... More >>asms|Castration Resistant Prostate Cancer (CRPC) Less << PHASE1|PHASE2 COMPLETED 2014-07-02 Chubu, Japan|Chugoku, Japan|Ho... More >>kkaido, Japan|Kansai, Japan|Kanto, Japan|Kyusyu, Japan|Shikoku, Japan Less <<
NCT01606982 Metastatic Castration-Resistan... More >>t Prostate Cancer Less << APPROVED_FOR_MARKETING - -
NCT01534052 Castration-Resistant Prostate ... More >>Cancer (CRPC) Less << PHASE2 COMPLETED 2017-04-18 Site US107, Aurora, Colorado, ... More >>80045, United States|Site US104, Chicago, Illinois, 60637, United States|Site US105, Pittsburgh, Pennsylvania, 15215, United States|Site US106, San Antonio, Texas, 78253, United States|Site MD37301, Chisinau, Moldova, Republic of|Site ZA2701, George, 6529, South Africa|Site ZA2702, Port Elizabeth, 6001, South Africa Less <<
NCT04290611 Prostate Cancer|Neuropathy|Epi... More >>lepsy|Encephalopathy Less << COMPLETED 2023-04-08 Centre d'Investigation Cliniqu... More >>e H?pital Pitié-Salpêtrière, Paris, 75013, France Less <<
NCT04456049 COVID-19 Infection PHASE2 TERMINATED 2021-06-09 Oncology Institute of Southern... More >> Switzerland (IOSI), Bellinzona, 6500, Switzerland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.22mL

10.77mL

2.15mL

1.08mL

21.53mL

4.31mL

2.15mL

References

 

Historical Records

Categories